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ABSTRACT
Kisspeptins (KP), peptide products of the kisspeptin-1 (KISS1) gene are the endogenous
ligands for a G protein-coupled receptor (KISS1R). KISS1 acts as a metastasis suppressor in
numerous human cancers. However, recent studies have demonstrated that an increase in
KISS1 and KISS1R expression in human breast tumors correlates with higher tumor grade and
metastatic potential. We have previously shown that KP-10, the most potent KP, stimulates
invasion of estrogen receptor (ER)-negative breast cancer cells via transactivation of the
epidermal growth factor receptor (EGFR). Here, I report that KP-10 treatment of the ERnegative non-malignant mammary epithelial MCF10A cells, or stable expression of KISS1R in
MCF10A and SKBR3 breast cancer cells stimulated cell invasiveness. KISS1R expression in
these cells induced a partial epithelial-to-mesenchymal transition (EMT)-like phenotype.
However, KP-10 had no effect on migration and invasion of the ER-positive T47D and MCF7
breast cancer cells. Furthermore, KP-10 stimulated EGFR transactivation in the ER-negative,
but not in the ER-positive cells. KP-10-stimulated cell migration, invasion and EGFR
transactivation were ablated upon stable expression of ERα in the ER-negative MDA-MB-231
cells. Lastly, I found that KISS1R was localized at the leading edge of motile cells, where it colocalized with the actin scaffolding protein, IQGAP1. Furthermore, I identified IQGAP1 as a
novel binding partner of KISS1R and have demonstrated that KISS1R regulates breast cancer
cell migration and invasion in an IQGAP1-dependent manner. Overall, these data reveal for the
first time that the ER status of mammary cells may dictate whether KISS1R signaling pathway
may be a novel target for breast cancer metastasis.
Keywords: Breast cancer, metastasis, cell migration, cell invasion, G protein-coupled receptor
(GPCR), kisspeptin (KP), KP receptor (KISS1R), epidermal growth factor receptor (EGFR),
epithelial-to-mesenchymal transition (EMT), three dimensional (3D) cultures, IQGAP1.
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CHAPTER 1: INTRODUCTION
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1.1. Breast Cancer
Breast cancer is the second leading cause of cancer-related deaths in Canadian
women, with the majority of these deaths resulting from metastasis of cancer to other
tissues (Canadian Cancer Society, 2012). In 2012, an estimated 22,700 Canadian women
will be diagnosed with breast cancer and 5,100 will suffer from cancer-related deaths. On
average, 62 Canadian women are diagnosed with breast cancer each day and 14 women
die of it every day (Canadian Cancer Society, 2012). When breast carcinomas are
confined to breast tissue, cure rates exceed 90%; however as cancer cells colonize
surrounding or distant tissues, long-term survival shows a pronounced decline (Martin et
al., 2005; Gupta and Massague, 2006; Geiger and Peeper, 2009). The dissemination of
cancer cells to secondary sites, resulting in disruption of normal tissue function is the
principal cause of fatality and the main impediment to improving prognosis in breast
cancer patients (Chambers et al., 2002; Martin et al., 2005).
Although many of the exact mechanisms and etiologies underlying the
development of human breast cancer are not fully understood, the most commonly
proposed model posits that invasive breast cancer initiates from the sequential and
compounded malignant transformation of epithelial cells that comprise either the
mammary ducts (ductal carcinoma in situ, DCIS) or the lobules of the mammary glands
(lobular carcinoma in situ, LCIS) (Sakorafas and Tsiotou, 2000; Cichon et al., 2010). The
early stages of the abnormal growth are typically classified as benign breast disease
(Sakorafas and Tsiotou, 2000; Cichon et al., 2010). Abnormal proliferation progresses
through stages during which the epithelium becomes increasingly proliferative, without
acquiring atypical characteristics (proliferative disease without atypia) (Cichon et al.,

3
2010). Atypical hyperplasia can manifest as either ductal or lobular forms (atypical
ductal hyperplasia or atypical lobular hyperplasia, respectively) (Cichon et al., 2010),
before it develops into DCIS or LCIS (Cichon et al., 2010). These abnormal epithelial
cells remain confined to the primary site of origin until they acquire additional genetic
alterations that render these cells capable of evading anti-growth and anti-apoptotic cues
and thus continue to proliferate in perpetuity (Sakorafas and Tsiotou, 2000). Progressive
growth and dedifferentiation produce cells that have acquired the ability to invade into
neighboring tissues or to more distant organs (Sakorafas and Tsiotou, 2000) (Figure
1.1).
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Figure 1.1. Breast cancer progression. Normal luminal epithelial cell growth becomes
unrestricted, resulting in ductal hyperplasia. Cells begin to lose their normal morphology,
progressing to an appearance indicative of ductal carcinoma in situ (DCIS). Progressive
growth and dedifferentiation may result in cells with invasive capabilities and metastasis
to distant sites. Schematic is adapted from the National Institutes of Health (NIH)
website (http://health.nih.gov/topic/BreastCancer/).
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1.1.1. Structure of the Mammary Gland
The human mammary breast epithelium is composed of a series of branched
parenchymal ductal networks that, during lactation, drain milk-producing alveoli into the
nipple (Cichon et al., 2010). The milk-producing structures of the mammary gland are
collections of multiple small acini at the distal ends of the ducts and are known as
terminal duct lobular units, and the entire epithelium is embedded within a collagenous
surrounding stroma (Cichon et al., 2010; Russo and Russo, 2011).
There are two main lineages of epithelial cells within the mammary epithelium: the
luminal (or apical) cells that line the central lumen and the underlying myoepithelial cells
that are adjacent to the basement membrane (Perou et al., 2000; Russo and Russo, 2011;
Valastyan, 2012). The basal layer of the mammary ductal epithelium is composed of
myoepithelial cells (Perou et al., 2000; Russo and Russo, 2011; Valastyan, 2012). The
two cell types may be distinguished by immunohistochemical analysis; luminal epithelial
cells stain with antibodies against simple cytokeratins 8/18/19, whereas basal epithelial
cells stain with antibodies against cytokeratin 5/6/14 (Petersen and Polyak, 2010). In
culture, luminal cells display standard epithelial cobblestone morphology, with junctional
complexes and apicobasal polarity, and express luminal/epithelial markers such as Ecadherin (Perou et al., 2000; Russo and Russo, 2011; Valastyan, 2012), whereas basal
cells exhibit expression of mesenchymal markers, such as N-cadherin, vimentin,
fibronectin and possess a spindle-like morphology (Perou et al., 2000; Russo and Russo,
2011; Valastyan, 2012) (Figure 1.2).
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Figure 1.2. Structure of a normal mammary acinus. The mammary epithelium
possesses an apico-basal polarized architecture surrounding a hollow lumen, surrounded
by an inner layer of luminal epithelial cells and an outer layer of myoepithelial cells.
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1.1.2. Breast Carcinoma Subtypes
Breast cancer presents as a molecularly and phenotypically heterogeneous disease,
displaying a variety of histopathological features, genetic markers and diverse prognostic
outcomes (Perou et al., 2000). Advances in microarray technology and transcriptional
profiling techniques have led to improvements in tumor classification (Perou et al.,
2000). Gene expression profiling has enabled a subdivision of tumors into five individual
subclasses (known as the Sorlie–Perou subtypes) found to convey a distinct prognostic
and biological message in breast cancer above and beyond established clinical markers
(Perou et al., 2000; Sorlie et al., 2001). The five groups are: luminal A, luminal B, basallike, ErbB2-positive (HER2-positive) and normal breast-like subtypes (Perou et al.,
2000; Sorlie et al., 2001). The majority of breast cancers arise from the luminal
epithelium of the small mammary ducts (Perou et al., 2000). Most newly diagnosed
breast cancers are classified as the luminal A subtype, which are typically estrogen
receptor (ER)-positive, low-grade, weakly proliferative and invasive and have a
favorable prognosis (Perou et al., 2000). Although the cellular origin of luminal A
tumors remains unresolved, these tumors are termed luminal because they display
epithelial phenotypic markers, such as E-cadherin and retain some degree of epithelial
organization (Perou et al., 2000). Luminal B tumors are also mostly ER-positive, but may
express low levels of hormone receptors and usually are of high-grade and have a higher
proliferation rate (Perou et al., 2000). The basal-like subtype, on the other hand, is often
characterized by triple-negative tumors (ER-, progesterone receptor (PR)-, and HER2negative). The ErbB2-positive subtype shows amplification and high expression of the
ErbB2 gene (also known as HER2, which is often constitutively active) (Perou et al.,
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2000). Lastly, there is the normal breast-like subtype, which displays expression of genes
generally present in the non-epithelial cell types, such as adipose tissue, shows strong
expression of basal epithelial genes, and minimal to non-existent expression of luminal
epithelial genes (Perou et al., 2000). However, it is unclear whether the latter subtype is a
unique group or represents poorly sampled tissue (Perou et al., 2000; Sorlie et al., 2001).
Given the heterogeneity and diversity of breast cancers, with clinical behavior that is
difficult to predict, prescribing an adequate treatment must take into account numerous
factors such as patient’s age, previous treatments, and co-morbidities. Moreover, the
molecular profile of the tumor usually takes the priority when making the ultimate
decision. Therefore, ER, PR and HER2 expressions help determine which treatment will
be most effective in combating the disease (Perou et al., 2000; Sorlie et al., 2001).

1.1.3. Estrogen Receptor Status
The steroid hormone estrogen plays a critical role in the development of the
mammary epithelium during puberty (Perou et al., 2000; Yan et al., 2010; Stingl, 2011;
Guttilla et al., 2012). Considering the role estrogen has in promoting mammary gland
development, it is not surprising that there is a strong positive correlation between
lifetime exposure to estrogen and breast cancer risk (Perou et al., 2000; Yan et al., 2010;
Stingl, 2011; Guttilla et al., 2012). The hormone estradiol (E2), acting through ERα, is
required for the normal growth and development of the mammary ductal network (Stingl,
2011; Rosen, 2012). ERα is an important prognostic indicator in breast cancer (Parl et al.,
1984), given that breast tumors are typically categorized as being ER-positive or ERnegative (Stingl, 2011). A significant fraction of cells within a luminal A tumor express
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ERα, and E2/ERα signaling promotes and sustains proliferation in these cells (Parl et al.,
1984; Perou et al., 2000; Guttilla et al., 2012). The expression of and dependence on ERα
in luminal A cancers form the rationale for hormonal therapies involving anti-estrogens
or aromatase inhibitors (Parl et al., 1984; Perou et al., 2000; Guttilla et al., 2012). The
E2/ERα signaling pathway promotes differentiation of mammary epithelia along a
luminal/epithelial lineage, in part through transcriptional stimulation of transcription
factors such as the trans-acting T-cell-specific transcriptional factor (GATA3) and
Forkhead box (FOX) (Eeckhoute et al., 2007; Yan et al., 2010; Guttilla et al., 2012;
Rosen, 2012). GATA3 is required for luminal differentiation in normal breast epithelia
and, furthermore, studies have shown that ERα and GATA3 stimulate each other
(Eeckhoute et al., 2007; Yan et al., 2010). FOXA1 is another ERα-interacting
transcription factor that is required to establish the luminal lineage in mammary epithelia
and specifically promotes ductal growth in mice (Eeckhoute et al., 2007; Yan et al.,
2010). FOXA1 promotes accessibility of estrogen-response elements for ERα binding
and stimulates ERα gene expression (Eeckhoute et al., 2007; Yan et al., 2010). In turn,
E2 appears to stimulate FOXA1 expression in breast cancer cells (Eeckhoute et al., 2007;
Yan et al., 2010). Hence, ERα, FOXA1 and GATA3 are all favorable prognostic
indicators in breast cancer (Eeckhoute et al., 2007; Yan et al., 2010). Given the
dependence of mammary development on ERα signaling, any perturbations within this
signaling pathway are likely to contribute to abnormalities in the homeostatic
maintenance of mammary tissue, ultimately leading to breast cancer.

10
1.1.4. Metastasis
Metastasis is the spread of a disease from one organ or part to another non-adjacent
organ or part (Fidler, 2003; Eccles and Welch, 2007; Geiger and Peeper, 2009).
Metastasis consists of a sequential, multistep cascade that must be completed to generate
a metastatic tumor (Fidler, 2003; Eccles and Welch, 2007; Geiger and Peeper, 2009).
Continual growth and survival of the tumor requires adequate blood supply to support its
metabolic requirements, which is achieved through the process of angiogenesis
(Chambers et al., 2002). The poorly organized architecture and increased permeability of
the new vasculature allows for cancerous cells to leave the primary site and enter the
systemic circulation and/or the lymphatic system through the process of intravasation
(Chambers et al., 2002).
At the cellular level, several processes facilitate motility and invasion of cancer
cells, including cytoskeletal reorganization of the filamentous actin, focal adhesion
formation and a transition from an epithelial to spindle-like morphology (Jiang et al.,
2009). The initial stages of cell motility are characterized by the formation of broad cell
membrane protrusions (lamellipodia) in the direction of the extracellular stimuli and the
attachment of thin actin-containing membrane projections (filopodia) to the extracellular
matrix (ECM) at sites of focal adhesions (Jiang et al., 2009). These events are followed
by contraction of the intracellular filamentous actin with subsequent disassembly of the
focal adhesion at the rear of the cell to ultimately allow the cell to be dragged forward in
a directional manner (Jiang et al., 2009). Cytoskeletal reorganization and cell movement
are regulated by several intracellular signaling pathways that are yet to be fully
elucidated. In addition to the capacity to migrate, tumor cells must acquire the ability to
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invade through surrounding tissues and vessels in order for metastasis to take place
(Geiger and Peeper, 2009). Proteases such as matrix metalloproteinases (MMPs) are
recruited to the leading edge of the cell, where they degrade and remodel the ECM
(Geiger and Peeper, 2009). The cells that survive in the circulation might extravasate and
settle in the surrounding tissue, where they must initiate and maintain growth for a
macroscopic tumor to form (Chambers et al., 2002). Although considerable progress has
been made in early detection of breast cancer and, consequently, lowering mortality,
metastatic breast cancer is a terminal disease and treatment goals focus on prolonging
survival and providing palliative care (Chambers et al., 2002; Gupta and Massague,
2006; Eccles and Welch, 2007; Geiger and Peeper, 2009; Tkaczuk, 2009).

1.1.5. Epithelial-to-Mesenchymal Transition
An understanding of the molecular and cellular underpinnings of metastasis is
required to develop targeted treatments against metastatic cells. At present, considerable
attention is being directed towards epithelial-to-mesenchymal transition (EMT) as the
probable first step in the complex process of metastasis (Hugo et al., 2007; Sarrio et al.,
2008; Micalizzi et al., 2010; Yan et al., 2010; Creighton et al., 2012; Guttilla et al.,
2012). EMT is defined as a multistep process, resulting in culmination of protein
modifications and transcriptional events in response to a defined set of extracellular
stimuli leading to a long term and sometimes reversible cellular changes (Hugo et al.,
2007). EMT has been described over the past decade as a process that is required for the
remodeling of cells and tissues during embryogenesis, wound healing, and during the
acquisition of malignant traits by carcinoma cells (Reya et al., 2001; Hugo et al., 2007;
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Mani et al., 2008; Polyak and Weinberg, 2009). One of the essential features
differentiating embryonic and tumorigenic or oncogenic EMT events is that the
tumorigenic processes involve genetically abnormal cells that progressively lose their
responsiveness to normal growth-regulatory cues and acquire the characteristics
associated with the hallmarks of cancer (Reya et al., 2001; Mani et al., 2008; Polyak and
Weinberg, 2009). EMT is mediated by specific molecular signals that promote the loss of
cell-cell junctions, cell-ECM adhesion and reorganization of the actin cytoskeleton
(Gupta and Massague, 2006; Hugo et al., 2007; Sarrio et al., 2008; Stingl, 2011; Guttilla
et al., 2012). This results in the loss of the apical polarity associated with epithelial cells
and gain of mesenchymal characteristics such as spindle-shaped morphology and a high
degree of motility (Gupta and Massague, 2006; Hugo et al., 2007; Sarrio et al., 2008;
Stingl, 2011; Guttilla et al., 2012) (Figure 1.3). The genetic and epigenetic changes
resulting in EMT are only one source of morphologic heterogeneity observed within
tumors (Reya et al., 2001; Mani et al., 2008; Polyak and Weinberg, 2009).
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Figure 1.3. Epithelial-to-mesenchymal transition (EMT). EMT occurs when epithelial
cells lose their epithelial cell characteristics, including dissolution of cell-cell junctions,
loss of apico-basal polarity, and acquire a mesenchymal phenotype, characterized by
actin cytoskeleton re-organization and stress fiber formation, increased migration and
invasion.
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Thus far, a large body of research has described stem cells in normal tissues,
capable of self-renewal, whilst concurrently generating committed progenitor cells,
whose descendants may eventually differentiate and carry out tissue-specific functions
(Reya et al., 2001). Moreover, recent studies have provided evidence of self-renewing,
stem-like cells within tumors, which have been called cancer stem cells (CSCs) (Reya et
al., 2001). Due to their ability to generate new tumors, these cells have been termed
tumor-initiating cells (Reya et al., 2001). During the process of metastasis, which is
often enabled by EMT, disseminated cancer cells would seem to require self-renewal
capability, similar to that exhibited by stem cells (Reya et al., 2001; Mani et al., 2008;
Polyak and Weinberg, 2009).
Multiple extracellular cues can initiate EMT events and there is a significant
crosstalk among the downstream intracellular signaling pathways and transcription
factors that choreograph this complex process (Reya et al., 2001; Hugo et al., 2007;
Polyak and Weinberg, 2009). The transcription factors such as Slug and Snail
(mesenchymal markers) induce EMT by repressing the transcription of E-cadherin
(epithelial marker) in numerous cancers, including breast cancer (Hugo et al., 2007).
Inhibition of E-cadherin transcription is often the first step triggering EMT as this
releases β-catenin, which is subsequently lost from the cell membrane and translocates to
the nucleus to participate in EMT signaling events (Hugo et al., 2007). Furthermore,
Snail family proteins repress E-cadherin transcription by binding the regulatory segments
on the E-cadherin promoter (Hugo et al., 2007). Reduction or absence of E-cadherin
expression is often accompanied by reciprocally increased expression of N-cadherin (a
mesenchymal marker) (Hugo et al., 2007). N-cadherin has been shown to promote breast
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cancer cell invasion (Hugo et al., 2007). The relevance of the mesenchymal phenotype
and the utility of multiple mesenchymal markers such as N-cadherin and vimentin to aid
in identifying EMT events, were reinforced by Zajchowski and colleagues, who found
that vimentin and other mesenchymal gene products were part of a 24 gene signature
predicting breast carcinoma cell invasiveness (Zajchowski et al., 2001).
It is well established that ERα activation is mitogenic in that it promotes growth of
the primary lesion, but is nevertheless able to keep EMT process in check (and therefore
is anti-metastatic) up to a point (Guttilla et al., 2012; Rosen, 2012). E2/ERα antagonizes
pathways that lead to EMT (Guttilla et al., 2012; Rosen, 2012). For instance,
transforming growth factor beta (TGF-β) has been shown to induce EMT in human
mammary epithelial cells and overexpression of the EMT-inducing factor Snail in MCF7
cells increased TGF-β signaling and cell invasiveness, and decreased adhesion and ERα
expression (Hajra et al., 2002; Eeckhoute et al., 2007; Creighton et al., 2012; Guttilla et
al., 2012). More recently, Ye and colleagues

examined the effects of either

overexpression of ERα in ERα-negative breast cancer cell lines (MDA-MB-468, MDAMB-231) or ERα knockdown in ERα-positive cell lines (MCF7, T47D) on the expression
of Slug and Snail and the resulting phenotypes (Ye et al., 2008; Ye et al., 2010).
Overexpression of ERα repressed Slug (but had no effect on Snail), increased protein
expression levels of E-cadherin and induced cells to grow as adherent colonies with
reduced invasiveness (Ye et al., 2008; Ye et al., 2010). In contrast, knockdown of ERα
resulted in elevation of Slug expression, and subsequent loss of E-cadherin expression
(Ye et al., 2008; Ye et al., 2010). Thus, ERα modulates EMT in breast cancer cells.
Furthermore, in a recent study Prasad and colleagues provided clinical evidence in
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support of Wnt/β-catenin to formation of invasive ductal carcinomas (Prasad et al.,
2009).
Growing evidence suggests that EMT is an essential regulator of cellular plasticity
in carcinomas and has important roles in therapeutic resistance, tumor recurrence and
metastatic progression (Reya et al., 2001; Hugo et al., 2007; Mani et al., 2008; Polyak
and Weinberg, 2009). Owing to its clinical importance of the EMT-induced processes,
inhibition of EMT is an attractive therapeutic approach that could potentially have
significant effects on the disease outcome.

1.2. Kisspeptins and Kisspeptin Receptor

1.2.1. Discovery and Distribution
The metastasis of cancer cells hinges upon a series of choreographed cascade of
events; hence, interruption of any step should effectively halt the process. Metastasis
suppressors, defined by their abilities to inhibit metastasis without blocking orthotopic
tumor growth are an attractive collection of contenders to treat metastasis (Beck and
Welch, 2005). Over a decade ago, a new metastasis suppressor gene was identified and
named KISS1 gene in reference to its place of discovery - Hershey, Pennsylvania, the
home of the famous Hershey Kisses (Lee and Welch, 1997a). The KISS1 gene encodes a
145-amino acid protein, which is subsequently cleaved into a 54-amino acid fragment,
which in turn may be cleaved by furin or prohormone convertases (deduced by the
presence of pairs of basic residues flanking this sequence) into even shorter, biologically
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active secreted peptides (10, 13, 14 amino acids long), collectively referred to as
kisspeptins (KPs) (Kotani et al., 2001; Ohtaki et al., 2001; Mead et al., 2007) (Figure
1.4). Currently, it is unclear whether the shorter forms are breakdown products (Kotani
et al., 2001). KPs are categorized as members of the Arg-Phe (RF)-amide family due to
the C-terminal amidation site that leads to strong binding affinity with their receptor (Lee
et al., 1999; Clements et al., 2001; Muir et al., 2001; Ohtaki et al., 2001; Stafford et al.,
2002; Kutzleb et al., 2005). In humans, reverse transcriptase polymerase chain reaction
(RT-PCR) revealed KISS1 mRNA to be present with high levels in the brain, breast,
pancreas, placenta, testis, liver, heart and small intestine (Lee et al., 1996; Muir et al.,
2001; Ohtaki et al., 2001; Kirby et al., 2010).
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Figure 1.4. The kisspeptins (KPs). Cleavage of KP-145 results in the production of
smaller peptides, designated KP-54 (metastin), KP-14, KP-13, and KP-10.
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KP-10, the most potent KP, is the smallest active peptide comprised of the last ten
amino acids of the full 145-amino acid peptide (Gutierrez-Pascual et al., 2009). The
structure of KP-10 is highly conserved across a range of species, differing from the
human and primate sequence only by a single amino acid in rat, mouse, platypus, sheep,
and cow (Kirby et al., 2010). It was revealed through saturation binding experiments that
KP-10 exhibited a KD of 1.0 ± 0.1nM (Kotani et al., 2001; Ohtaki et al., 2001; Kirby et
al., 2010). Furthermore, KP-10 exhibited greater potency than KP-54 (5.47 ± 0.03nM),
KP-14 (7.22 ±0.07 nM), or KP-13 (4.62 ± 0.02nM), with an EC50 of 4.13 ± 0.02nM
(Kotani et al., 2001; Ohtaki et al., 2001; Kirby et al., 2010).
Although the sequence for KISS1 gene has been known since its initial discovery, it
was not until 2001 that the peptide products of KISS1 were identified as the endogenous
ligands for the KP receptor (KISS1R; formerly known as AXOR12, GPR54 or
hOT7T175) by three independent groups (Kotani et al., 2001; Muir et al., 2001; Ohtaki
et al., 2001). The KISS1R mRNA displays similar tissue distribution as its ligand, with
high levels expressed in the placenta, pituitary gland, pancreas, breast and spinal cord
(Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001). KISS1R mRNA is also
abundant in the heart, skeletal muscle, kidney, liver, and placenta, and also in regions of
the central nervous system (Clements et al., 2001). Radioligand binding of

125

I-KP-14

was detected in aorta, coronary artery and umbilical vein (Mead et al., 2007), suggesting
expression of the KISS1R in the vasculature.
In a recent study, Roseweir and colleagues reported on the derivation of a
KISS1R antagonist, termed Peptide-234 (P-234) (Roseweir et al., 2009; Kirby et al.,
2010). P-234 was discovered by systematically substituting amino acid residues in the
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KP-10 sequence and the resulting compounds were evaluated for their ability to block
KP-10-induced inositol phosphate (IP) release in Chinese hamster ovary (CHO) cells
stably expressing KISS1R (Roseweir et al., 2009; Kirby et al., 2010). P-234 contains
seven residues conserved from KP-10, it showed an IC50 of 7.0nM, and competed for the
binding of

125

I-KP-10 with an affinity of 2.7nM (Roseweir et al., 2009; Kirby et al.,

2010). P-234 was demonstrated to inhibit the firing of gonadotropin-releasing hormone
(GnRH) neurons in the brain of the mouse and to reduce pulsatile GnRH secretion in
female pubertal monkeys (Pineda et al., 2009; Roseweir et al., 2009). Furthermore, P234 inhibited the KP-10-induced release of luteinizing hormone (LH) in rats and mice
and blocked the post-castration rise in LH in sheep, rats, and mice (Roseweir et al.,
2009). Therefore, the development of KISS1R antagonists provides a valuable tool to
investigate the roles of the KP-10/KISS1R signaling pathway in physiological and
pathophysiological states (Pineda et al., 2009; Roseweir et al., 2009; Kirby et al., 2010).

1.2.2. KP/KISS1R Signaling
KISS1R is a canonical G protein-coupled receptor (GPCR), which couples to the
Gαq/11 signaling pathway, activating phospholipase C (PLC), which results in
phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis, followed by accumulation of
inositol-(1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG) to cause subsequent
calcium mobilization (Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001).
Consequently, an increase in intracellular calcium concentration could induce hormone
release as observed in the reproductive system, or mediate inhibition of cell proliferation
(Stafford et al., 2002), as it has been shown in some cancer cells (Lamprecht and Lipkin,
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2001). Other signaling pathways activated by KP/KISS1R seem to be cell typedependent, and proposed downstream mediators include protein kinase C (PKC),
mitogen-activated protein kinases (MAPKs; such as extracellular signal-regulated kinase
(ERK) 1/2 and p38), and phosphatidylinositol-3-kinase/Akt (Kotani et al., 2001; Muir et
al., 2001). Thus, a unique pattern of activation of transduction signals selectively
regulates biological functions by the KP/KISS1R system in a cell type-dependent manner
(Figure 1.5). The diversity of the pathways activated by the KP/KISS1R system to exert
its distinct functions are yet to be fully understood and the mechanisms by which
KP/KISS1R signals are yet to be resolved.
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Figure 1.5. Molecular signaling of the KPs via KISS1R. KISS1R is a Gq/11 proteincoupled receptor (GPCR), resulting in the activation of phospholipase C (PLC), protein
kinase C (PKC), and members of the mitogen-activated protein kinase (MAPK) pathway,
including extracellular signal-regulated kinase (ERK)1/2, p38, and phosphatidylinositol3-kinase (PI3K).
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One of the principal mechanisms for switching off many GPCRs is homologous
desensitization, a process that involves the co-ordinated actions of two families of
proteins, the GPCR kinases (GRKs) and β -arrestins (Freedman and Lefkowitz, 1996;
Krupnick and Benovic, 1998). GRK-mediated GPCR phosphorylation specifically
prepares the activated receptor for arrestin binding (Luttrell and Lefkowitz, 2002).
Arrestin binding to the receptor blocks further G protein-mediated signaling, targets
receptor for internalization to the endosomes via clathrin-coated pits (for recycling) or
lysosomes (for degradation), and redirects signaling to alternative G protein-independent
pathways (Luttrell and Lefkowitz, 2002). Pampillo and colleagues were the first to
demonstrate that KISS1R is constitutively associated with GRK2 and β-arrestins-1 and 2, and that these interactions are mediated through residues in the second intracellular
loop and cytoplasmic tail of KISS1R (Pampillo et al., 2009). Additionally, they showed
that KISS1R undergoes GRK-dependent desensitization in human embryonic kidney
(HEK) 293 cells and that β-arrestin-2 mediates KISS1R activation of ERK1/2 in MDAMB-231 breast cancer cells (Pampillo et al., 2009). Furthermore, recent studies by this
group have also shown that β-arrestin-1 inhibits, whereas β-arrestin-2 and Gq/11 activate
ERK1/2 in a co-dependent manner following KISS1R activation (Szereszewski et al.,
2010). Since KISS1R is emerging as a GPCR of immense clinical importance,
understanding the molecular mechanisms that regulate KISS1R signaling upon receptor
activation is necessary to evaluate its potential as a therapeutic target.
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1.2.3. Physiological Roles of KP/KISS1R Signaling
Since the discovery of the KPs and their receptor, numerous reports about
KP/KISS1R signaling have appeared, ranging from reproductive endocrinology,
cardiovascular physiology, in addition to cancer biology. The crucial role that KPs and
their receptor play in the regulation of the reproductive axis was first indicated by
observations of loss-of-function mutations in the KISS1R in some patients with idopathic
hypogonadotropic hypogonadism (de Roux et al., 2003; Seminara et al., 2003) and
confirmed in transgenic mouse models (Funes et al., 2003; Seminara et al., 2003;
Kauffman et al., 2007). KPs have since been identified as major regulators of the
hypothalamic-pituitary-gonadal (HPG) axis, governing pubertal onset in an increasing
number of species.
1.2.3.1. Reproductive Endocrinology
There is substantial evidence that the KISS1R signaling is required for the onset of
puberty. KP activation of

KISS1R

exerts a role in the neuroendocrine control of

reproduction by regulating GnRH (de Roux et al., 2003; Funes et al., 2003; Seminara et
al., 2003; d'Anglemont de Tassigny et al., 2007; Kauffman et al., 2007; Lapatto et al.,
2007). Kiss1r-null mice experience a delayed onset of puberty or are unable to proceed
through puberty altogether, with both sexes appearing to have immature sexual organs
(de Roux et al., 2003; Funes et al., 2003; Seminara et al., 2003; d'Anglemont de
Tassigny et al., 2007). Furthermore, Kiss1 and/or Kiss1r gene deletion significantly
reduced testicle size in male mice (Lapatto et al., 2007). LH and follicle-stimulating
hormone (FSH) serum levels were also decreased in male Kiss1r-null mice, whereas this
was not observed in female mice (Lapatto et al., 2007). Subcutaneous injection of KP-54
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resulted in increased levels of LH and FSH (with the exception of the Kiss1r-null mice),
indicating the crucial roles of Kiss and Kiss1r in GnRH release from the hypothalamus
(Lapatto et al., 2007). In addition to mice, humans with mutations of the KISS1R or
KISS1 gene fail to go through puberty (de Roux et al., 2003; Funes et al., 2003; Seminara
et al., 2003; d'Anglemont de Tassigny et al., 2007; Kauffman et al., 2007; Lapatto et al.,
2007). Contrary to the effects of decreased KP levels, KP administration can induce
precocious puberty (Navarro et al., 2005), whereas central injection of the KISS1R
antagonist (P-234) counteracts the effects of KPs in that it delays puberty (Pineda et al.,
2009) in pre-pubertal rats.
1.2.3.2. Pregnancy and Placentation
In addition to the well established role of KP/KISS1R system in the regulation of
the HPG axis, this signaling pathway has been proposed to have significant effects on
other physiological systems, such as pregnancy and placentation. Initial studies of KISS1
gene expression reported high levels of this protein in the human placenta (Lee et al.,
1996; Muir et al., 2001; Ohtaki et al., 2001; Kirby et al., 2010). More specifically, KP
and KISS1R expression has been demonstrated to be higher in the first trimester than in
the third trimester placentas, correlating with reduced invasiveness of placental tissue
(Janneau et al., 2002; Horikoshi et al., 2003). A radioimmunoassay revealed that in male
and non-pregnant female humans, plasma KP circulates at very low concentrations
(Dhillo et al., 2006). However, during pregnancy, plasma KP concentrations display a
1000-fold increase in the first trimester, rising to a 10,000-fold increase in the third
trimester (Horikoshi et al., 2003).
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In addition, the KP/KISS1R signaling pathway plays a major role in regulation of
trophoblast invasion to allow remodelling of the maternal arteries, to provide sufficient
blood flow to the developing fetus (Bilban et al., 2004). KP-10, the form found in
placenta (Bilban et al., 2004) has been shown to inhibit migration of primary trophoblast
explants and this is associated with a decrease in MMP expression (Bilban et al., 2004).
1.2.3.3. Cardiovascular System
Recently it has been suggested that KPs may play a role in regulating the
cardiovascular system, given that KP and KISS1R expression has been detected in
human, rat and mouse myocardium and vasculature (Nijher et al., 1111; Mead et al.,
2007; Kirby et al., 2010; Ramaesh et al., 2010; Maguire et al., 2011; Sawyer et al.,
2011). Additionally, Mead and colleagues have identified presence of both KISS1 and
KISS1R mRNA in human aorta, umbilical vein and coronary artery (Mead et al., 2007).
Moreover, KPs have been shown to act as positive inotropes (modulators of force of
muscular contraction) in the atria of these three species (Maguire et al., 2011). It was
further suggested that KPs act as vasoconstrictors in vivo as KPs stimulated contraction
of human vessels with comparable potency to angiotensin II (Ang II), a potent vasoactive
peptide (Mead et al., 2007). In a different study, Ramaesh and colleagues have shown
that KP-10 induced concentration-dependent inhibition of proliferation and migration of
the human umbilical vein endoethelial cells (HUVEC), however KP-10 had no effect on
the viability or apoptosis of these cells (Ramaesh et al., 2010). Furthermore, KP-10 has
been shown to inhibit angiogenesis by interfering with vascular endothelial growth factor
(VEGF) signaling (Ramaesh et al., 2010). Nevertheless, Nijher and colleagues have
shown that elevation of plasma KP does not alter blood pressure in humans (Nijher et
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al., 1111). Therefore, a growing body of evidence suggests that the KP/KISS1R system
has the ability to regulate cardiovascular system by modulating vasoconstriction and
angiogenesis.

1.2.4. KP/KISS1R Signaling in Cancer
To date, the metastasis suppressor activity of the KP/KISS1R system has been
identified in numerous cancers, including thyroid (Ringel et al., 2002; Stathatos et al.,
2005), ovarian (Gao et al., 2007; Hata et al., 2007; Zhang et al., 2008), bladder (SanchezCarbayo et al., 2003a), gastric (Dhar et al., 2004; Guan-Zhen et al., 2007), esophageal
(Ikeguchi et al., 2004), pancreatic (Masui et al., 2004) and lung (Zohrabian et al., 2007)
cancers. KISS1R activity was shown to repress MMP-9 activity, inhibit migration and
invasion, increase tissue inhibitor of metalloprotease (TIMP)-1 production and activate
focal adhesion kinase (FAK), leading to the formation of excessive focal adhesions and
stress fibre formation (Kotani et al., 2001).
Numerous studies have confirmed that a reduction in KISS1 expression correlates
with poor prognosis in cancer patients. One of the first clinical studies evaluating the role
of KPs in human cancer was performed in melanomas, where KISS1 mRNA expression
was examined at various stages of melanoma progression and found to be reduced in
large primary melanomas and in metastases (Shirasaki et al., 2001). Additionally, in
gastric cancers, KISS1 mRNA expression in patients with distant metastases (lymph
node, liver metastases) was significantly reduced (Dhar et al., 2004). In another gastric
cancer study, analysis of KP protein expression was reduced in lymph node and liver
metastases compared to primary gastric tumors (Guan-Zhen et al., 2007). In another
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study, comparing plasma KP-54 levels, pancreatic cancer patients were found to have
higher plasma KP-54 levels compare to healthy individuals (Katagiri et al., 2009).
Collectively, these findings are intriguing in that they establish KPs as an important
prognostic indicator in gastric and pancreatic cancers and suggest the potential
significance of plasma KP levels within patients (Guan-Zhen et al., 2007; Katagiri et al.,
2009).
In another clinical study, KISS1 and KISS1R mRNA expression have been shown
to be independent markers of favorable prognosis in patients with clear-cell subtype
ovarian carcinoma (Prentice et al., 2007). A loss of KISS1 and KISS1R has been found to
be a strong prognostic factor for lymph node metastasis of esophageal squamous cell
carcinomas, given that the loss of KISS1 and/or KISS1R gene expression was detected in
86-100% of primary tumors in cases with lymph node metastasis (Ikeguchi et al., 2004).
Finally, in bladder tissue, 80% of invasive tumors showed little to no expression of
KISS1, compared to normal urothelium that displayed high expression of this gene
(Sanchez-Carbayo et al., 2003b). Thus, as indicated by these studies, KISS1 and/or
KISS1R expression could potentially prove useful prognostic markers in clinical settings.
Thus far, numerous types of cancers, including melanoma, gastric carcinoma,
esophageal squamous cell carcinoma, pancreatic cancer and bladder cancer have shown
that signaling of the KPs and KISS1R may have anti-metastatic and tumor-suppressant
effects. Nevertheless, studies are emerging that indicate that KP/KISS1R may act in a
pro-metastatic fashion. For example, in hepatocellular cancers, KP acts in a prometastatic fashion (Ikeguchi et al., 2003; Hou et al., 2007; Schmid et al., 2007).
Additionally, a recent study found that plasma KP-54 levels were elevated in patients
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with colorectal cancer and the authors speculated that the measurement of plasma KP-54
levels could be a useful diagnostic and prognostic parameter for patients with colorectal
cancer (Canbay et al., 2012). Additionally, we have reported that KP/KISS1R system
may positively regulate breast cancer cell invasion (Zajac et al., 2011).
1.2.4.1. KP/KISS1R Signaling in Breast Cancer
The role of KPs in breast cancer has been difficult to discern. In a 1997 study by
Lee and colleagues, the human ‘breast’ cancer cell line MDA-MB-435 which is KISS1negative was transfected with the KISS1 construct, and subsequently these cells were
injected in athymic nude mice, resulting in a decrease in the number of macroscopic lung
metastases compared to the non-transfected parental cells (Lee and Welch, 1997b).
Therefore, in addition to anti-metastatic capacity of KPs in melanoma, the authors
suggested that KISS1 could also function as a metastasis suppressor of the MDA-MB-435
cells (Lee and Welch, 1997b). The authors went as far as to suggest that KISS1 may
inversely correlate with the progression of breast tumors, and thus may in fact be used as
a prognostic marker in breast cancer patients (Lee and Welch, 1997a). The findings of
this study had not been questioned until the controversial debate regarding the origins of
MDA-MB-435 cells. Characterization of this cell line in 2000 has shown that the pattern
of gene expression for MDA-MB-435 more closely resembled that of melanoma cell
lines, rather than that of other breast tumor lines (Ross et al., 2000). Therefore, in the
breast cancer field, it is now generally accepted that the studies performed using these
cells have to be conducted with caution (Chambers, 2009).
This controversy provided a gateway for a 2005 landmark study performed by
Martin and colleagues, the first study of its kind to investigate the expression of KISS1
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and its receptor in human breast cancer tissues. KISS1 mRNA expression was elevated in
tumor tissue compared to normal healthy mammary tissue as measured by quantitativePCR (q-PCR)analysis, which was supported by immunohistochemistry (Martin et al.,
2005). Additionally, node positive tumors showed significantly increased KISS1 mRNA
levels compared to node negative tumors, yet no differences were observed in KISS1R
mRNA levels (Martin et al., 2005). This study has also shown that the introduction of the
KISS1 construct into human breast cancer MDA-MB-231 cells increased their
invasiveness and decreased their adhesive property using in vitro assays (Martin et al.,
2005). Therefore, overexpression of KISS1 was correlated with poor prognosis in breast
cancer patients and was proposed to act as a possible promoter of invasion in human
breast cancer cells (Martin et al., 2005).
Differential regulation of KISS1 and KISS1R mRNA levels by steroid hormones
has been reported to occur due to the direct effect of E2, as ERα is expressed within KPimmunoreactive cells present in the preoptic area and arcuate nucleus of the ovine
hypothalamus (Franceschini et al., 2006). ERα-mediated pathways play a vital role in
breast carcinogenesis, and thus, ERα level is consensually used as a prognostic marker of
breast tumors and of the response to endocrine therapy (Clarke et al., 2004). In a 2007
study, Marot and colleagues reported a significant E2-induced decrease in KISS1 mRNA
level in adenovirus ERα- and adenovirus ERβ-infected ER negative MDA-MB-231
breast cancer cells, when compared with adenovirus control-infected cells (Marot et al.,
2007). Conversely, tamoxifen administration upregulated KISS1 and KISS1R expression
in ERα-positive breast tumor cells (Marot et al., 2007). To provide further support to this
conclusion, among ERα-positive tumor samples from patients treated with tamoxifen,
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patients with shorter disease-free survival had elevated expression of KISS1 and KISS1R
(Marot et al., 2007). Recently, activator protein 2 alpha (AP-2α) has been described as a
possible positive transcriptional regulator of KISS1 in breast cancer cell lines via
interaction with specificity 1 protein (Sp1) (Mitchell et al., 2007). It has also been shown
that E2 rapidly down-regulates endogenous KISS1 mRNA in a stable ERα-expressing
MDA-MB-231 cell line (Huijbregts and de Roux, 2010). E2-induced down-regulation of
KISS1 mRNA is mediated by a pathway combining ribonucleic acid polymerase II
(RNAPII) loss at the proximal promoter and modulation of active RNAPII along the gene
body, which is a novel mechanism in the complex process of E2-induced repression of
KISS1 gene expression (Huijbregts and de Roux, 2010).
To date, one study has investigated whether KP/KISS1R signaling regulates breast
cancer metastasis in vivo. A mouse model that is widely used to investigate the
relationship between human and mouse breast cancer development and metastasis is the
polyoma virus middle T antigen (PyMT) under the control of the mouse mammary tumor
virus (MMTV) promoter (MMTV-PyMT) transgenic model (Lin et al., 2003). MMTVPyMT mice show widespread transformation of the mammary epithelium and
development of multifocal mammary adenocarcinomas and metastatic lesions in the
lymph nodes and in the lungs (Lin et al., 2003). The close similarity of this model to
human breast cancer is also exemplified by the fact that in these mice there is a gradual
loss of steroid hormone receptors (estrogen and progesterone) is observed (Lin et al.,
2003). In a recently published study, Cho and colleagues (2011) have shown that Kiss1r
heterozygosity (Kiss1r+/−) delayed PyMT-induced breast cancer development and
metastasis in mice. More specifically, Kiss1r heterozygosity attenuated breast tumor
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initiation, growth, latency, multiplicity and metastasis induced in MMTV-PyMT/Kiss1r
mouse models (Cho et al., 2011). Orthotopic injection into NOD.SCID/NCr mice of
isolated mouse primary breast cancer MMTV-PyMT/Kiss1r+/− cells showed attenuated
breast tumor growth compared to MMTV-PyMT/Kiss1r+/+ cells (Cho et al., 2011). To
confirm the roles of human KISS1R for tumorigenicity in human breast epithelium, nonmalignant

human

mammary epithelial

MCF10A cells

were transformed by

overexpressing the constitutively active H-Ras (H-RasV12) to induce tumorigenesis (Cho
et al., 2011). Overexpression of the active H-RasV12 transformed the MCF10A breast
epithelial cells and induced anchorage-independent colony growth on soft agar (Cho et
al., 2011). Knockdown of KISS1R using specific shRNA for human KISS1R reduced
Ras-induced anchorage-independent colony formation, suggesting that human KISS1R
plays a vital role in Ras-induced MCF10A cell tumorigenesis (Cho et al., 2011). To date,
the mechanisms by which KP/KISS1R regulates breast cancer cell migration and
invasion, two processes required for metastasis remain largely unknown. Recent studies
from our laboratory have demonstrated that KP-10, the most potent KP, stimulates breast
cancer cell migration and invasion of ER-negative MDA-MB-231 and Hs578T that
endogenously express KISS1R, via transactivation of epidermal growth factor receptor
(EGFR) (Zajac et al., 2011), a known pharmacological target, that is upregulated in
numerous cancers, including breast cancer (Eccles, 2011).
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1.3. The Epidermal Growth Factor Receptor
The human epidermal growth factor receptor (EGFR)/HER/ErbB family comprises
of four closely related receptor tyrosine kinases (RTKs): ErbB1/EGFR/HER1 (hereafter
termed EGFR), ErbB2/EGFR2/HER2 (hereafter termed HER2), HER3, and HER4 (Lurje
and Lenz, 2009). Each member of the ErbB family has a similar structure consisting of a
large extracellular domain, a single transmembrane-spanning domain, an intracellular
juxtamembrane region, a tyrosine kinase domain and a C-terminal regulatory region
(Ferguson, 2008; Liebmann, 2011).
Numerous ligands can bind and activate EGFR, including epidermal growth factor
(EGF), TGF-α, amphiregulin, heparin-binding EGF, and betacellulin (Herbst, 2004).
Binding of the ligand to the receptor leads to homodimerization or heterodimerization of
the receptor, followed by internalization of the dimerized receptor (Herbst, 2004). Once
the dimerized receptor becomes internalized, autophosphorylation of the cytoplasmic
EGFR tyrosine kinase domains occurs (Franklin et al., 2002). These phosphorylated
tyrosine residues serve as binding sites for enzymes (e.g., phospholipase Cγ1 (PLCγ1)) or
adaptor proteins (e.g. Grb2 or Shc) containing Src homology 2 (SH2) domains (Franklin
et al., 2002; Wetzker and Bohmer, 2003; Liebmann, 2011). The principal signaling
cascades of RTKs that ultimately result in the modulation of various downstream targets
include: MAPKs, PI3K family, members of the signal transducers and activator of
transcription family, and the PLCγ1pathway (Liebmann, 2011). Given that these
signaling systems are vital in development, it is not unexpected that their activation
results in multiple co-ordinated cell responses in normal cells, but these are subverted by
overexpression/misregulation in pathological processes such as cancer.
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1.3.1. EGFR in Cancer
The influence of growth factor-driven signaling in pathogenesis has been long
recognized. ErbB receptors, their ligands and their signaling are essential in the control of
cell proliferation, survival, differentiation and deregulated signaling of these receptors
has been extensively studied as potential targets for inhibition of tumor growth and
progression (Liebmann, 2011). Deregulation of ErbB signaling pathways has been
described in many cancers, including breast, linked to a multiplicity of molecular
mechanisms including epigenetic mechanisms, activating mutations of the receptors
themselves or activation induced by autocrine/paracrine ligands (Eccles, 2011). EGFR is
overexpressed in the majority of solid tumors, including breast cancer, head-and-neck
cancer, non-small-cell lung cancer, renal cancer, ovarian cancer, and colon cancer
(Herbst and Langer, 2002). Additionally, overexpression of the receptor occurs also in a
smaller percentage of bladder cancers, pancreatic cancers, and gliomas (Salomon et al.,
1995; Herbst and Langer, 2002). Such overexpression produces excessive activation of
downstream signaling pathways, resulting in cells displaying more aggressive growth and
metastatic potential (Herbst and Langer, 2002; Herbst, 2004). In particular,
overexpression of HER2, which occurs in 25% to 30% of breast cancers, is associated
with poor prognosis and shorter survival (Slamon et al., 1987). EGFR expression was
found to be higher in patients with nodal or distant metastases than in those without
(Sutton et al., 2010). Mutations in EGFR are rare in breast cancer, but it is amplified in
some cases (such as metaplastic subtype) (Burness et al., 2010) and it is also highly
expressed in basal breast cancers, a subset of triple negative breast cancers (TNBC)
(Eccles, 2011). TNBC are characterized by a lack of expression (or minimal expression)
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of ER and PR as well as an absence of HER2 overexpression (Eccles, 2011). TNBCs
represent 10-17% of all breast cancers, are more common in certain non-Caucasian
ethnic groups (e.g. those of African descent) and tend to occur at less than 50 years of
age (Eccles, 2011). These cancers are also generally of high grade and show distinct
patterns of metastasis; notably visceral, liver and brain involvement, leading to a
particularly poor prognosis (Dawson et al., 2009). TNBC is particularly prevalent in
women carrying a breast cancer type 1 susceptibility protein (BRCA1) gene mutation and
EGFR overexpression is found in 67% of BRCA1 related cancers compared to 18% of
sporadic cancers (Eccles, 2011). Using human mammary epithelial cell (hMEC) cultures
it has been demonstrated that even partial suppression of BRCA1 function induced
EGFR expression and an increase in EGFR-positive cancer stem-like cells, suggesting
that this receptor could provide a growth advantage at early stages of transformation
(Eccles, 2011).
EGFR and HER2 have been the main receptors considered as targets for
immunotherapeutic approaches in breast cancer, mainly via antibody-based therapies
(Ladjemi et al., 2010; Eccles, 2011). Trastuzumab, a humanised anti-HER2 monoclonal
antibody targeting the juxtamembrane region of the extracellular domain, has been
successful in clinical trials, particularly in combination with standard chemotherapy and
in adjuvant settings (Goel et al., 2011). Trastuzumab is reportedly most active in tumors
driven by HER2 homodimers and is also effective in combination with anti-endocrine
therapies in ER-positive tumors (Goel et al., 2011). Pertuzumab is another humanised
antibody that inhibits HER2 heterodimerization with other family members by binding to
the dimerization loop of the former (i.e a different site from trastuzumab). It has shown
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some promise in HER2 breast and ovarian cancer patients and is also being evaluated in
combination with trastuzumab or chemotherapy (CLEOPATRA trials) (Baselga and
Swain, 2010). In general, HER2-targeted therapies are only effective in cancers with
gene amplifications, and sensitive assays are needed to determine those who may benefit
(e.g. HercepTest or Oncotype Dx).
Unfortunatley, some HER2-positive breast cancer patients treated with trastuzumab
can become resistant. Hence, understanding the molecular mechanisms underlying HER2
signaling and trastuzumab resistance is vital to reduce breast cancer mortality (White et
al., 2011). IQ motif containing guanine triphosphatase activating protein 1 (IQGAP1) is a
ubiquitously expressed scaffolding protein that contains multiple protein interaction
domains (White et al., 2011). By regulating its binding partners IQGAP1 integrates
signaling pathways, several of which contribute to breast tumorigenesis. White and
colleagues have shown that IQGAP1 is overexpressed in HER2-positive breast cancers
and binds directly to HER2 (White et al., 2011). Furthermore, IQGAP1 is overexpressed
in trastuzumab-resistant breast epithelial cells, and reducing IQGAP1 both augments the
inhibitory effects of trastuzumab and restores trastuzumab sensitivity to trastuzumabresistant breast cancer cells (White et al., 2011). These data suggest that inhibiting
IQGAP1 function may represent a rational strategy for treating HER2-positive breast
carcinoma.

1.3.2. IQGAP1 in Cancer
IQGAP1 is a ubiquitously expressed scaffolding protein with multiple binding
partners which allow for integration of diverse signaling pathways (Briggs and Sacks,
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2003; Brown and Sacks, 2006). Proteins that are known to bind IQGAP1 include actin,
calmodulin, E-cadherin, β-catenin, components of the MAPK pathway (White et al.,
2011) and EGFR (McNulty et al., 2011). By interacting with these proteins, IQGAP1
regulates multiple cellular activities, such as cytoskeletal organization, cell-cell adhesion,
cell migration, gene transcription and signal transduction (Briggs and Sacks, 2003;
Brown and Sacks, 2006). For example, binding of IQGAP1 to β-catenin both disrupts the
E-cadherin-catenin complex, inhibiting epithelial cell-cell adhesion (Kuroda et al., 1996)
and increases β-catenin-mediated transcriptional activation (Briggs and Sacks, 2003).
Accumulating evidence strongly supports a role for IQGAP1 in tumorigenesis
(Johnson et al., 2009; White et al., 2011). More than 50% of the identified IQGAP1
binding partners have defined roles in neoplastic transformation and tumor progression,
and many cellular functions regulated by IQGAP1 are important in cancer biology
(Johnson et al., 2009; White et al., 2011). IQGAP1 is upregulated in numerous human
cancers, including breast carcinoma (Jadeski et al., 2008), oligodendroglioma (French et
al., 2005) and colorectal carcinoma (Bertucci et al., 2004). In addition, overexpression of
IQGAP1 stimulates tumorigenesis of human breast epithelial cells (Jadeski et al., 2008).
Modulating IQGAP1 expression levels in malignant human breast epithelial cells
significantly alters their tumorigenicity (Mataraza et al., 2003; Jadeski et al., 2008).
Overexpression of IQGAP1 enhances in vitro motility and invasion of both MCF7 and
MDA-MB-231 cells (Mataraza et al., 2003; Jadeski et al., 2008). Conversely, siRNAmediated knockdown of IQGAP1 reduces MCF7 anchorage-independent growth,
motility and invasion in vitro, as well as growth and invasion in vivo (Jadeski et al.,
2008). Collectively, these data suggest that IQGAP1 overexpression contributes to
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tumorigenesis of human breast epithelium. These findings support the concept that
IQGAP1 functions as an oncogene (Johnson et al., 2009; White et al., 2011). To further
implicate IQGAP1 relevance in breast cancer, IQGAP1 was found to be overexpressed in
trastuzumab-resistant human breast epithelial cells and knockdown of IQGAP1 both
enhances the inhibitory effects of trastuzumab in vitro and abrogates trastuzumab
resistance (White et al., 2011). These findings imply that IQGAP1 is a potential target for
the development of additional therapeutic strategies for patients with HER2-positive
breast cancers.

1.3.3. Signaling Cross-Talk between GPCR-EGFR
Over the last decade, significant progress has been made in understanding the
complexity of GPCR-RTK signaling. Once seen as isolated receptors connecting
extracellular stimuli to the activation of G proteins, GPCRs are now regarded as complex
receptors capable of initiating a vast array of G protein-dependent and -independent
signaling cascades, including signaling and interacting both directly and indirectly with
other receptor families through the involvement of scaffolding molecules (Freedman and
Lefkowitz, 1996; Fischer et al., 2003; Wetzker and Bohmer, 2003; Liebmann, 2011).
RTKs such as the EGFR are overexpressed in numerous cancers where signaling through
this receptor contributes to cell survival, proliferation, and invasion (Thomas et al., 2006;
Rodland et al., 2008). Inhibition of EGFR alone using RTK inhibitors, although highly
promising in preclinical models has resulted in limited anti-metastatic effects due to
acquired resistance to these agents (Engelman and Janne, 2008).
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An interesting example of non-classical information integration is the ability of
GPCR-mediated RTK transactivation. It is well established that GPCR-mediated EGFR
transactivation results in increased migration and invasion, hallmarks of the metastatic
process (Thomas et al., 2006). Numerous GPCRs have been shown to increase motility
and invasion of cancer cells through mechanisms involving the transactivation of EGFR.
These include the protease-activated receptor-1 (PAR-1) (Arora et al., 2007),
lysophosphasitic acid receptor 1 (LPA1-R) (Shida et al., 2008), bombesin (Chao et al.,
2009) and chemokine receptor 4 (CXCR4) (Kasina et al., 2009). Additionally, GPCRmediated EGFR transactivation may participate not only in cancer development and
progression, but also has been found to influence clinical responses to EGFR-targeted
therapies. For example, cell-specific crosstalk between GPCRs and EGFR has been
reported for various cancer types such as lung, breast, prostate, ovarian, colon, and head
and neck cancers (Fischer et al., 2003; Kalyankrishna and Grandis, 2006).
Recently, we have demonstrated that KISS1R mediates EGFR transactivation in
highly aggressive human breast cancer cell lines to promote their migration and invasion
(Zajac et al., 2011). Given the clinical importance of understanding the mechanism by
which KISS1R may regulate cell transformation, invasion and metastasis, I set out to
determine the influence of KISS1R signaling in non-malignant human mammary
MCF10A epithelial cells and to determine the mechanism by which KISS1R signaling
promotes breast cancer cell migration and invasion. MCF10A cells were chosen to
investigate the effect of KP-10/KISS1R signaling on the acquisition of a malignant
phenotype.
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1.4. Rationale and Hypothesis
Findings in humans:
Martin and colleagues first reported that expression of KISS1 and KISS1R mRNA
and protein levels were elevated in human breast cancer tissues using real-time PCR and
immunohistochemistry, respectively (Martin et al., 2005). This study found a positive
correlation between KISS1 and KISS1R mRNA expression with increases in breast tumor
grade (Martin et al., 2005). Additionally, patients with high KISS1 and KISS1R mRNA
have shown the shortest relapse-free survival (Marot et al., 2007). To provide further
support to this conclusion, another study reported that among ERα-positive tumor
samples from patients treated with tamoxifen, patients with shorter disease-free survival
had elevated expression of KISS1 and KISS1R mRNA (Marot et al., 2007).
Finding from animal models:
Recently, Cho and colleagues (2011) have shown that loss of KISS1R decreased
tumor growth in vivo in immunocompromised mice. They have also shown that Kiss1r
heterozygosity (Kiss1r+/−) attenuated breast tumor initiation, growth, latency and
metastasis induced in MMTV-PyMT/Kiss1r mouse models (Cho et al., 2011). The
authors demonstrated that knockdown of KISS1R in the H-RasV12-transformed
MCF10A cells reduced anchorage-independent colony formation, suggesting that human
KISS1R plays a key role in Ras-induced MCF10A cell tumorigenesis (Cho et al., 2011).
Findings from the Bhattacharya laboratory:
We have previously shown that KP-10, the most potent KP stimulates ER-negative
breast cancer cell invasion concomitant with MMP-9 secretion and activity, and have
implicated β-arrestin 2 in this process (Zajac et al., 2011). We found that treatment of
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ER-negative breast cancer cells with KP-10 results in the transactivation of EGFR, and
this is required for KP-10-stimulated invasion (Zajac et al., 2011). Furthermore, we
discovered that KISS1R directly complexes with EGFR, and that stimulation of breast
cancer cells with either KP-10 or EGF regulates the endocytosis of KISS1R and EGFR
(Zajac et al., 2011). However, the role of endogenous KP/KISS1R signaling in nonmalignant mammary epithelial cells and the mechanism by which KP/KISS1R stimulates
migration and invasion is still unclear and was examined in this study.

Hypothesis: KP-10 signaling via KISSIR will not stimulate invasion and motility of nonmalignant mammary epithelial MCF10A cells.

1.5. Objectives
To determine:
Aim 1) Whether or not KP-10/KISS1R signaling promotes migration and invasion of
non-malignant mammary epithelial MCF10A cells.
Aim 2) Whether or not KP-10 promotes invasion and migration of ER-positive T47D and
MCF7 breast cancer cells.
Aim 3) The mechanism by which KISS1R regulates breast cancer cell migration and
invasion.
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1.6. Significance
Gaining a better understanding of the molecular pathways involved in cell
migration and invasion is expected to be vital in the identification of novel targets for the
design of new therapeutics for cancer patients. The proposed studies will reveal the
underlying mechanisms by which KISS1R signaling regulates cell invasiveness,
shedding light on whether or not the ER status of breast epithelia influences KISS1R
signaling and targeting KISS1R in breast cancer is a potentially useful therapy.
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CHAPTER 2: METHODS AND RESULTS
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2.2. Materials and Methods
Cell culture. The cell lines used in this study are summarized in Table 2.1. Cell lines
were purchased from ATCC (Manassas, VA), some of which were genetically modified
as presented in Table 1. Cells were maintained at 37°C with 5% CO2. Human breast
cancer cells, MDA-MB-231, MDA-MB-231 pcDNA3.1, MDA-MB-231 ERα, MDAMB-231 pSuperRetro Renilla B (Scrambled), MDA-MB-231 pSuperRetro siIQGAP1 #1
(siIQGAP1 #1), MDA-MB-231 pSuperRetro siIQGAP1 #2 (siIQGAP1 #2), T47D,
SKBR3, SKBR3 pFLAG-A1 and SKBR3 FLAG-KISS1R were cultured in RPMI 1640
(Invitrogen, Burlington, Ontario, Canada) supplemented with 10% (v/v) fetal bovine
serum (FBS, Sigma). MCF7 breast cancer cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% (v/v) FBS and 0.3% insulin.
MCF10Ca1h cells were cultured in DMEM supplemented with 10% (v/v) FBS.
MCF10A, MCF10A pFLAG-A1 (vector control), MCF10A FLAG-KISS1R (generated
from a single clone), and MCF10A FLAG-KISS1R heterogenous pooled cell population
(from here on referred to as MCF10A FLAG-KISS1R mixed) were grown in mammary
epithelial basal medium (MEBM; Clonetics-Cambrex) supplemented with a MEGM
Single Quots kit (bovine pituitary extract, human epidermal growth factor, insulin,
hydrocortisone, gentamicin/amphotericin) and cholera toxin at 100ng/mL.
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Table 2.1. Summary of the human cell culture models used in the study.

CELL
LINES

CHARACTERISTICS OF THE
PARENTAL CELL LINE
Human Mammary Epithelial Cells

MCF10A
Derivatives:
 MCF10A pFLAG-A1
 MCF10A FLAG-KISS1R
 MCF10A FLAG-KISS1R mixed

 Non-malignant mammary epithelial
cells isolated from a patient with
fibrocystic desease (Soule et al.,
1990)
 Non-motile, non-invasive (Soule et al.,
1990)
 ERα-negative (Petersen and Polyak,
2010)
 Express KISS1R endogenously (Cho
et al., 2011)

Human Breast Cancer Cell Lines
MCF10Ca1h

 Malignant mammary epithelial cell
line derived from a pre-malignant
mammary epithelial MCF10AT cells
(Santner et al., 2001)
 ERα-negative (Santner et al., 2001)

T47D

 Infiltrating ductal carcinoma (Keydar
et al., 1979)
 ERα-positive (Keydar et al., 1979)
 Express KISS1R endogenously (Marot
et al., 2007)

MCF7

 Invasive ductal carcinoma (Soule et
al., 1973)
 ERα-positive (Soule et al., 1973)
 Express KISS1R endogenously (Marot
et al., 2007)

SKBR3
Derivatives:
 SKBR3 pFLAG-A1
 SKBR3 FLAG-KISS1R

 Moderately invasive, HER2overexpressing breast carcinoma
(Trempe, 1976)
 ERα-negative (Trempe, 1976)
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Table 2.1. Summary of the human cell culture models used in the study
(continuation).

CELL
LINES

CHARACTERISTICS OF THE
PARENTAL CELL LINE
Human Breast Cancer Cell Lines

MDA-MB-231
Derivatives:
 MDA-MB-231 pcDNA3.1
 MDA-MB-231 ERα
 MDA-MB-231 Scrambled
 MDA-MB-231 siIQGAP1#1
 MDA-MB-231 siIQGAP1 #2

 Highly invasive breast
adenocarcinoma (Cailleau et al.,
1974)
 ERα-negative (Cailleau et al., 1974)
 Express KISS1R endogenously
(Martin et al., 2005)
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Stable transfections and gene knockdowns. FLAG-KISS1R and pFLAG-A1 (vector
control) constructs were generated as described (Oved et al., 2006; Pampillo et al.,
2009) and obtained from Dr. Andy Babwah. MCF10A cells (1 x 106 cells) were
transfected with 5µg cDNA constructs by microporation (1700V, 10 pulse width, 3#)
using the NeonTM Transfection System (Invitrogen) according to the manufacturer’s
instructions. MDA-MB-231 cells were transfected with either pcDNA3.1 or ERα
constructs (a generous gift from Dr. Bonnie Deroo; (Deroo et al., 2004)) (5µg/1 x 106
cells in 100µL) by microporation as described above. A heterogeneous population of
stable transfectants was selected by using media containing 750µg/mL G418
(Invitrogen). To silence IQGAP1 expression, a Bio-Rad microporator was used to
transfect 6.0 x 105 cells with two individual siRNA constructs that targeted IQGAP1 or a
scrambled control (generously provided by Dr. David Sacks (NIH, Bethesda, MD)) as
described (Mataraza et al., 2003). The siRNA against IQGAP1 targets the 4959-4977
nucleotide region of the IQGAP1 mRNA with +1 representing the first nucleotide of the
first codon. Stable heterogenous population of cells was selected by culturing in
puromycin (1mg/mL) and mixed population cells (siIQGAP#1 and #2) generated with
two different siIQGAP1 constructs as described (Mataraza et al., 2003), showing the best
knockdown (as was verified by Western blot analysis) were chosen for the rest of the
experiment.

Cell migration and invasion assays. Transwell chamber migration and invasion assays
were performed as previously described (Li et al., 2009; Zajac et al., 2011). Briefly,
transwell filters (8µm pores) were placed into a 24-well plate containing either serum-
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free medium or medium supplemented with 10% FBS. Cells were serum-starved for 4
hours. T47D (1.5 x 105), MCF7 (1.0 x 105), MDA-MB-231 pcDNA3.1, MDA-MB-231
ERα, MDA-MB-231 scrambled, MDA-MB-231 siIQGAP1 #1 or MDA-MB-231
siIQGAP1 #2 (4.0 x 104) cells were plated in the upper chamber in either serum-free
medium or serum-free medium supplemented with 10nM or 100nM KP-10 (Phoenix
Pharmaceuticals; Burlingame, CA) and incubated for 20 hours. For invasion assays,
filters were coated with 1 in 10 dilution of Matrigel dissolved in serum-free RPMI 1640
(9.4mg/mL stock, BD Biosciences). The top of the filter was scraped to remove cells that
did not migrate or invade. Cells were then fixed using a solution of 20% acetone and
80% methanol and nuclei were stained using 0.1% Hoechst 33258 (Invitrogen,
Burlington, Ontario, Canada). Two replicates were conducted for each condition, and ten
random fields of the filter were imaged using an Olympus IX-71 inverted microscope.
The average number of cells (nuclei) that migrated or invaded were counted. Results are
presented as a ratio of cells that migrated relative to cells that migrated in control
conditions (cells seeded in serum-free media and migrating towards 10% (v/v) FBSsupplemented appropriate medium). Results are from at least three independent
experiments.

3D Matrigel invasion assays. Typical mononolayer cultures of mammary epithelial
cells do not closely mimic the features of cells and tissue architecture in vivo (Weaver et
al., 1995; Weaver and Bissell, 1999). Moreover, they do not recapitulate the genetic
modifications acquired during growth and progression of breast tumors (Lelievre et al.,
1998). Both normal and malignant breast cells can be cultured in reconstituted
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extracellular matrix as a three-dimensional (3D) model, resembling the in vivo microenvironment (Li et al., 2009; Zajac et al., 2011). To determine the oncogenic potential of
KISS1R in breast cells, the ability of non-malignant human mammary epithelial
MCF10A cells and moderately invasive SKBR3 stably expressing either FLAG-KISS1R
or pFLAG-A1 (vector control), to form organotypic invasive structures in 3D invasion
assay was examined. Cells were seeded in a 1:1 dilution of phenol red-free Matrigel and
culture medium at 2.5 × 104 cells/mL on Matrigel-coated 35mm glass-bottomed culture
dishes (Mattek, Ashland, MA). Cultures were overlaid with culture medium and
maintained for up to three weeks in the presence of 10nM or 100nM KP-10 or left
untreated. Cell colonies were scored blindly as being either stellate or spheroidal after
growth in Matrigel. A colony was deemed to be stellate if one or more projections from
the central sphere of cells were observed. To examine the effect of KP-10 on invasion of
ER-positive breast cancer cells, 3D Matrigel invasion assays were also performed with
T47D and MCF7 cells (with the same conditions kept as for the MCF10A and SKBR3
cells). Images were taken with an Olympus IX-81 microscope (Olympus, Center Valley,
PA), using InVivo Analyzer Suite (Media Cybernetics).

Scratch assays for cell motility. T47D, MCF7, MCF10A, MCF10A pFLAG-A1 or
MCF10A FLAG-KISS1R cells were seeded into a 12-well dish in appropriate culture
medium and allowed to grow to confluency. Cells were then serum-deprived in serumfree medium for 4 hours. The scratch was made with a sterile pipette tip passed across the
monolayer. Cells were then treated with 10nM KP-10 in appropriate media supplemented
with FBS (5% for MCF10A and stable transfectants, 10% for MDA-MB-231 cells). For
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the experiments with the KISS1R antagonist - Peptide-234 (P-234; Phoenix
Pharmaceuticals (Burlingame, CA) was dissolved in 20% acetonitrile in sterile water
(vehicle). Cells were pre-treated with P-234 in serum-free medium for 4 hours, and then
stimulated in the presence or absence of P-234 and allowed to migrate for the duration of
the experiment. Cells were allowed to migrate into the scratch for 24 hours and
visualized every 60 minutes using an Olympus IX-81 microscope (Olympus). Distance
travelled (in µm) was then measured over the course of the 24 hours, using duplicates for
each condition and seven fields per duplicate. Data were analyzed using ImagePro
software (Media Cybernetics) and graphed as a function of time.

Cell growth assays. To measure cell growth in monolayer culture, 4.0 x 105 MCF10A
pFLAG-A1 or MCF10A FLAG-KISS1R cells were initially seeded into 60mm dishes. At
24 hour intervals (24, 48, 72), duplicate samples (2 dishes per day) were trypsinized and
the number of cells was enumerated using a hemocytometer.

MTT cell viability assays. MTT cell viability assays (Cell Signaling) were conducted as
described (Li et al., 2009), according to the protocol of the manufacturer. Briefly, 5.0 x
104 cells (MCF10A pFLAG-A1, MCF10A FLAG-KISS1R or MDA-MB-231) were
plated in 96-well plates and stimulated with 10nM KP-10 dissolved in FBS (5% or 10%
for MCF10A pFLAG-A1 and FLAG-KISS1R or MDA-MB-231 cells, respectively), in
the presence or absence of P-234. Cells were then incubated with 0.5mg/mL of MTT
labeling agent (3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide) for 4 h
and subsequently solubilized for 24h. Absorbance was measured at 570nm using a
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SpectraMax M5 MultiMode Microplate Reader (Molecular Devices) with a background
subtraction at 750nm.

KP-10-stimulated EGFR transactivation. These experiments were conducted as
previously described (Zajac et al., 2011). T47D, MCF7, SKBR3, MDA-MB-231
pcDNA3.1, MDA-MB-231 ERα, MCF10A, MCF10A pFLAG-A1, MCF10A FLAGKISS1R, MCF10A FLAG-KISS1R mixed or MCF10A-CA1h were cultured to 80%
confluency, serum-starved for 24 hours to attenuate basal EGFR activity and then
stimulated with various ligands for the indicated times. After stimulation, cultures were
washed with ice-cold phosphate-buffered saline (PBS) and were solubilised in lysis
buffer (20 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 2 mM Na3VO4, 1
mM NaF, 10% glycerol, 1% Triton X-100) containing protease inhibitors (1 µL/mL
aprotinin, 1 µL/mL leupeptin and 10 µL/mL AEBSF). Lysates (850 µg of total protein)
were used for immunoprecipitation studies. EGFR was immunoprecipitated using a
rabbit polyclonal anti-EGFR antibody (1:100, Upstate Millipore) and protein Gsepharose beads (Sigma) over-night at 4°C. Immunoprecipitated proteins were resolved
by 7.5% SDS-PAGE, and then semi-dry transferred onto a 0.45µm nitrocellulose
membrane. Phosphorylation of EGFR was examined probing the membrane with a
mouse monoclonal anti-phosphotyrosine antibody (PY-20, Santa Cruz), diluted in Tris
Buffered Saline-Tween 20 (TBS-T) containing 1% bovine serum albumin (BSA) at
1:1000. Membranes were rinsed with TBS-T and then incubated with enhanced
chemiluminescence (ECL) anti-mouse horseradish peroxidase (HRP)-conjugated IgG
used at 1:3000 dilution and visualized by ECL Western blotting detection reagents
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(Fisher, Nepean, Ontario, Canada). Western blots were then re-probed with rabbit
polyclonal anti-EGFR antibody (1:4000, Upstate Millipore) to assess total EGFR. ECL
anti-rabbit HRP-conjugated IgG was used at 1:3000 dilution in 1% bovine serum
albumin (BSA) dissolved in TBS-T and subsequently proteins were visualized using ECL
detection reagents (Fisher, Nepean, Ontario, Canada). Densitometric analysis was done
using VersaDoc Imaging System (Bio-Rad).

Inositol phosphate production assays. These experiments were conducted as we have
previously described (Aziziyeh et al., 2009; Pampillo et al., 2009). MCF10A, MCF10A
pFLAG-A1, MCF10A FLAG-KISS1R or MCF10A FLAG-KISS1R mixed cells were
incubated overnight with 1 μCi/mL [3H]myo-inositol in DMEM to radiolabel inositol
lipids. Unincorporated [3H]myo-inositol was removed by washing the cells with HBSS.
Cells were incubated for one hour in HBSS at 37°C and then incubated in 500μL of the
same buffer containing 10mM LiCl for an additional 15 minutes at 37°C. Next, the cells
were incubated either in the absence or presence of 100nM KP-10 for one hour at 37°C.
The reaction was stopped on ice by adding 500μL of 0.8M perchloric acid and then
neutralized with 400μL of a solution containing 0.72M KOH and 0.6M KHCO3. Total
[3H]inositol incorporated into the cells was determined by counting the radioactivity
present in 50μL of the cell lysate. Total IP was purified from the cell extracts by anion
exchange chromatography using AG® 1-X8 (analytical grade, 200-400 mesh, formate
form) resin (Bio-Rad). [3H]IP formation was determined by LS 6500 Scintillation
Counter (Beckman). The means ± SEM are shown for the number of independent
experiments indicated in the figure legends.
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Co-immunoprecipitations.

Co-immunoprecipitation

assays

were

conducted

as

previously described (Aziziyeh et al., 2009; Li et al., 2009; Zajac et al., 2011). MDAMB-231 pFLAG-A1 or MDA-MB-231 FLAG-KISS1R cells were serum-starved for 4
hours, and subsequently they were left untreated or stimulated for the indicated times
with 100nM KP-10. Cells were solubilized in lysis buffer (20mM HEPES, 150mM NaCl,
1.5mM MgCl2, 1% Triton X-100, protease inhibitors). Cell lysates (850 µg of total
protein) were used for co-immunoprecipitation studies. FLAG-tagged receptor was
immunoprecipitated using a rabbit monoclonal anti-FLAG antibody and protein GSepharose beads (Sigma) over-night at 4°C. Immunoprecipitated proteins were separated
by SDS-PAGE and IQGAP1 expression was examined using a rabbit monoclonal antiIQGAP1 antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, California) and
visualized by ECL, following the manufacturer’s protocol.

Immunofluorescence microscopy. MCF10A, MCF10A pFLAG-A1, or MCF10A
FLAG-KISS1R cells were serum starved for 4 hours. Cells were washed three times,
fixed and permeabilized with 4% paraformaldehyde (PFA) along with 0.2% Triton-X at
room temperature for 20 minutes. Cells were incubated with the following antibodies:
goat anti-GPR54 (N-20) sc-48220, (1:50, Santa Cruz Biotechnology), rabbit anti-Ecadherin (1:350, BD), rabbit anti-Snail/Slug (1:500, Santa Cruz Biotechnology), mouse
anti-N-cadherin (1:500, BD) or phalloidin (1:100, Molecular Probes) conjugated to Alexa
Fluor (AF) 555 for 1 hour and then washed 3 times. The following AF secondary
antibodies were used: AF 555 anti-goat (1:250, Invitrogen), AF 568 anti-rabbit (1:250,
Invitrogen) or AF 488 anti-mouse (1:250, Invitrogen). Images were acquired using an
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LSM-510 META laser scanning microscope (Zeisss, Oberkochen, Germany) using a
Zeiss 63X objective, oil immersion lens.

Statistical Analysis. One-way analysis of variance (ANOVA) with a Dunnett’s post-hoc
test or two-way ANOVA followed by Bonferroni post-hoc test were performed using
GraphPad Prism 5 (GraphPad Software, Inc.). Differences were considered statistically
significant at P < 0.05.

2.3. Results

KISS1R stimulates invasion of non-malignant mammary epithelial cells. We have
previously reported that KP-10 increases migration and invasion of the highly invasive
ER-negative MDA-MB-231 breast cancer cells in a dose-dependent manner, starting at
10nM and with a maximal response obtained using 100nM KP-10 (Zajac et al., 2011).
Therefore, all of the subsequent studies were performed using either 10 or 100nM KP-10,
which is in accordance with published literature (Navenot et al., 2005; Pampillo et al.,
2009). To test my hypothesis that KP-10/KISS1R signaling will not stimulate motility
and invasion of non-malignant mammary epithelial MCF10A cells, I first sought to
determine the effect of KP-10 treatment on MCF10A cells, using 3D Matrigel invasion
assays. Treatment with either 10nM or 100nM KP-10 significantly stimulated MCF10A
cells, which endogenously express KISS1R (Cho et al., 2011) to form invasive structures
compared to untreated cells (Figure 2.1).
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In order to assess the role for KISS1R signaling in mediating the invasive
phenotype in MCF10A cells, a stable cell line expressing KISS1R was generated from a
single clone, named MCF10A FLAG-KISS1R cells. The exogenous expression of
FLAG-KISS1R was verified by immunoprecipitation experiments (Figure 2.2A) and by
immunofluorescence microscopy. Endogenous KISS1R in MCF10A cells cultured in 3D
was detected by immunofluorescence microscopy using a commercially available
KISS1R (N-20) antibody (Figure 2.2B). Antibody binding to antigen was blocked by
pre-absorption with the blocking peptide (Figure 2.2B). Expression of FLAG-KISS1R
was detected using an anti-FLAG antibody (Figure 2.2C); confocal Z-stacks illustrate
the staining pattern of the receptor. The endogenous expression of KISS1R in MCF10A
cells and the exogenous expression of KISS1R in MCF10A FLAG-KISS1R cells
exhibited a similar localization to the cell surface membranes and intracellularly (Figure
2.2B, Figure 2.2C).
To examine the effects of stable exogenous expression of KISS1R in MCF10A
cells on cell invasion, MCF10A FLAG-KISS1R cells were grown in 3D Matrigel
cultures. These cells exhibited invasive structures, even in the absence of KP-10 (Figure
2.3A). On the contrary, MCF10A pFLAG-A1 (vector control) cells showed an increase
in invasive stellate structure formation only when treated with KP-10 (both 10nM and
100nM) (Figure 2.3A), as was observed with the MCF10A parental cells (Figure 2.1).
To rule out any effects due to clonal selection, a pooled population of MCF10A FLAGKISS1R cells (named MCF10A FLAG-KISS1R mixed) was generated. MCF10A FLAGKISS1R mixed cells also invaded both in the presence and absence of KP-10 (Figure
2.3B), thus corroborating observation with the MCF10A FLAG-KISS1R cells. Therefore,
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these results reveal that treatment of non-malignant and non-invasive MCF10A cells with
KP-10, or expression of KISS1R in these cells induces an invasive phenotype.

KISS1R expression stimulates invasiveness of the ER-negative SKBR3 breast
cancer cells. To corroborate the observations that KISS1R expression stimulates
invasiveness, I expressed KISS1R in another ER-negative, weakly invasive cell line - the
SKBR3 breast cancer cell line. KP-10 did not induce invasive structure formation in
SKBR3 pFLAG-A1 (vector control) cells (Figure 2.4A). However, stable expression of
KISS1R in SKBR3 cells induced the formation of invasive structures both in presence
and absence of either 10nM or 100nM KP-10 (Figure 2.4B). Thus, KISS1R expression
induces an invasive phenotype in the ER-negative MCF10A (Figure, 2.1, Figure 2.3A,
Figure 2.3B) and SKBR3 (Figure 2.4B), in addition to ER-negative MDA-MB-231 and
Hs578T breast cancer cells (Zajac et al., 2011).
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Figure 2.1. KP-10 stimulates invasion of non-malignant mammary epithelial
MCF10A cells. Treatment of MCF10A cells with either 10 or 100nM KP-10
significantly increases invasive stellate structure formation in 3D cultures, when
compared to untreated cells (n=5). Two-way ANOVA followed by Bonferroni post-hoc
test: a, P<0.05 for 10nM KP-10 when compared to untreated cells; b, P<0.05 for 100nM
KP-10 when compared to untreated cells. Scale bar, 100 µm.
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Figure 2.2. KISS1R expression in MCF10A and stable transfectants. (A) KISS1R
expression in MCF10A FLAG-KISS1R stables. Immunoprecipitation with a rabbit
polyclonal anti-FLAG antibody, followed by Western blot analysis with a goat
polyclonal KISS1R (N-20) antibody reveals expression of FLAG-KISS1R in MCF10A
FLAG-KISS1R stables. β-Actin, loading control (n=3). (B) Endogenous expression of
KISS1R in MCF10A parental cells grown in 3D Matrigel cultures. KISS1R
immunofluorescence was detected using goat polyclonal KISS1R (N-20) followed by
anti-goat Alexa Fluor 555 (red). Presence of the blocking peptide against N-20 ablated
immunofluorescence observed with N-20 (n=3). (C) Localization of KISS1R in
MCF10A FLAG-KISS1R cells grown in 3D Matrigel cultures. Confocal microscopy
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(displaying three sequential Z-stacks) of FLAG-KISS1R immunofluorescence was
detected using a rabbit polyclonal FLAG antibody followed by anti-rabbit Alexa Fluor
568 (red). Nuclei stained using Hoechst (blue) (n=3). Scale bar, 20 µm.
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Figure 2.3. KISS1R expression stimulates invasion of non-malignant mammary
epithelial MCF10A cells. Stable expression of FLAG-KISS1R in MCF10A cells (A)
monoclonal population and (B) mixed pooled population induces stellate colony
formation in 3D cultures, both in the presence and in the absence of KP-10. MCF10A
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pFLAG-A1 (vector control) cells only invade in the presence of KP-10 (n=3). Two-way
ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for 10nM KP-10 MCF10A
pFLAG-A1 (vector control) cells when compared to untreated MCF10A pFLAG-A1
(vector control) cells; b, P<0.05 for 100nM KP-10 MCF10A pFLAG-A1 (vector control)
cells when compared to untreated MCF10A pFLAG-A1 (vector control) cells. Scale bar,
100 µm.
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Figure 2.4. Stable KISS1R expression stimulates invasion of SKBR3 breast cancer
cells. (A) KP-10 does not induce stellate colony formation in SKBR3 pFLAG-A1 (vector
control) cells in 3D cultures (n=3). (B) Stable expression of FLAG-KISS1R in SKBR3
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cells induces stellate colony formation, both in the presence and in the absence of KP-10
in 3D cultures (n=3). Scale bar, 100 µm.
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KISS1R stimulates motility of mammary epithelial cells. Cell motility is required for
many important physiological processes and unregulated cell motility can be the cause
for progression of cancer. In order to visualize whether or not activation of KISS1R by
KP-10 stimulates MCF10A cell motility, scratch assays were performed, as we have
previously described (Zajac et al., 2011). Addition of KP-10 (10nM) significantly
enhanced the distance travelled by MCF10A cells, compared to cells stimulated with
medium supplemented with 5% FBS (Figure 2.5A). When KP-10 was dissolved in
medium lacking FBS (i.e., serum-free medium), no migration was observed (data not
shown), as we have previously reported in the MDA-MB-231 cells (Zajac et al., 2011).
Furthermore, 10nM KP-10 significantly stimulated cell motility in MCF10A pFLAG-A1
(vector control) and MCF10A FLAG-KISS1R cells, compared to cells seeded only in 5%
FBS (Figure 2.5B). To exclude the confounding effects of FBS on cell proliferation, cell
growth assays were performed to determine the doubling time of these cells. Both
MCF10A pFLAG-A1 and MCF10A FLAG-KISS1R had a doubling time that was greater
than 72 hours (Figure 2.5C). Thus, this suggests that the effects of KP-10 on scratch
closure are due to motility and not due to proliferation. Therefore, KP-10 significantly
enhances motility of the ER-negative non-malignant MCF10A cells and stables.
To investigate whether the KISS1R is localized to the leading edge of cells, which
is consistent with a role in cell migration, we examined the distribution of KISS1R in
migrating MCF10A and MCF10A FLAG-KISS1R cells. A well established marker for
the leading edge of migratory cells is the actin scaffolding protein IQGAP1, which
interacts with actin filaments to cross-link them (Mataraza et al., 2003; Noritake et al.,
2005; Brown and Sacks, 2006). After wounding a confluent monolayer of cells,
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immunofluorescence microscopy showed that endogenous KISS1R was localized to the
leading edge of migrating MCF10A cells, where it co-localized with IQGAP1 in
lamellipodia (Figure 2.6A). Furthermore, in MCF10A FLAG-KISS1R cells, KISS1R
was also localized to the leading edge, where it co-localized with IQGAP1 (Figure
2.6B). Taken together, these results suggest that KISS1R activation not only induces
MCF10A and MCF10A FLAG-KISS1R cells to invade, but also plays a role in cell
motility.
We have previously shown that KP-10 enhances cell motility of MDA-MB-231
breast cancer cells (Zajac et al., 2011). To verify a role of endogenous KISS1R signaling
in regulating cell motility, I have performed cell motility assays in the presence of a
KISS1R antagonist, P-234. KP-10-enhanced motility of MDA-MB-231 cells was
significantly blocked in the presence of P-234 (Figure 2.7A). Furthermore, treatment of
these cells with the antagonist did not affect cell viability (Figure 2.7B). These results
validate a role for endogenous KISS1R signaling in KP-10-induced breast cancer cell
migration.
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Figure 2.5. KISS1R stimulates motility of mammary epithelial cells. (A) Treatment
with 10nM KP-10 significantly enhances the distance closed of MCF10A cells in a
scratch assay over a 24 hour period (n=7). Two-way ANOVA followed by Bonferroni
post-hoc test: a, P<0.05 for serum-free when compared to 5% serum and 10nM KP-10;
b, P<0.05 for 5% serum when compared to 5% serum and 10nM KP-10; c, P<0.05 for
serum-free when compared to 5% serum. Scale bar, 100 µm. (B) Treatment of 10nM
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KP-10 significantly enhances the motility of MCF10A FLAG-KISS1R and MCF10A
pFLAG-A1 (vector control) cells in scratch assay (n=3). Two-way ANOVA followed by
Bonferroni post-hoc test: a, P<0.05 for 5% serum (MCF10A FLAG-KISS1R) when
compared to 5% serum and 10nM KP-10 (MCF10A FLAG-KISS1R); b, P<0.05 for 5%
serum (MCF10A pFLAG-A1) when compared to 5% serum and 10nM KP-10 (MCF10A
pFLAG-A1); c, P<0.05 for serum-free (MCF10A pFLAG-A1 or MCF10A FLAGKISS1R) when compared to 5% serum and 10nM KP-10 (MCF10A pFLAGA1/MCF10A FLAG-KISS1R); d, P<0.05 for serum-free (MCF10A pFLAG-A1 or
MCF10A FLAG-KISS1R) when compared to 5% serum (MCF10A pFLAGA1/MCF10A FLAG-KISS1R). Scale bar, 100 µm. (C) MCF10A pFLAG-A1 and
MCF10A FLAG-KISS1R cell proliferation at 0, 24, 48, 72 hours. 4.0 x 105 cells were
seeded, and counted every 24 hours using hemocytometer. Cell proliferation is expressed
as % Cell Number (set as 100% at the time of seeding (0 hours)). One-way ANOVA
followed by Dunnett’s multiple comparison test: *, P<0.05. Bars represent % Cell
Number ± SEM.
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Figure 2.6. KISS1R co-localizes with IQGAP1 in MCF10A and MCF10A FLAGKISS1R cells. KISS1R is localized to the leading edge of (A) MCF10A and (B)
MCF10A FLAG-KISS1R cells where it is co-localized with IQGAP1 in lamellipodia
(white arrowheads). Confocal micrographs showing KISS1R immunofluorescence using
a goat polyclonal N-20 KISS1R antibody followed by an anti-goat Alexa Fluor 555 (red);
IQGAP1 detected using a monoclonal anti-IQGAP1 antibody followed by an anti-mouse
Alexa Fluor 488 (green). Areas of co-localization are shown in overlay (yellow). Nuclei
stained using Hoechst (blue) (n=3). Scale bar, 20 µm.
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Figure 2.7. P-234 (KISS1R antagonist) inhibits KP-10-enhanced cell motility. (A)
MDA-MB-231 were treated with 1µM P-234 and subjected to a scratch assay over a 24
hour period (n=3). Two-way ANOVA followed by Bonferroni post-hoc test: a, P<0.05
for 10% FBS and 10nM KP-10 and 1µM P-234 when compared to 10% FBS and 10nM
KP-10, b, P<0.05 for 10% FBS and KP-10 and P-234 when compared to 10% FBS and
KP-10 and vehicle. (B) P-234 does not affect the viability of MDA-MB-231 cells. 5.0 x
104 cells were plated in 96-well plates and treated as indicated. Cells were then incubated
with 0.5mg/mL of MTT labeling agent for 4 h and subsequently solubilized for 24 hours
(n=3).
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KP-10 induces IP formation. KISS1R is a canonical GPCR, which signals via Gq/11 Gprotein, leading to production of second messengers DAG and IP3 (Kotani et al., 2001;
Muir et al., 2001). Since I found that KISS1R signaling stimulates MCF10A cells to
migrate and invade, I also assessed whether activation of KISS1R stimulated IP
formation in MCF10A, MCF10A pFLAG-A1, MCF10A FLAG-KISS1R and MCF10A
FLAG-KISS1R mixed cells. I found that stimulation of cells with 100nM KP-10 (in
media with 5% FBS) for one hour increased IP formation in each MCF10A cell line,
compared to cells incubated only in media with 5% FBS (Figure 2.8). However,
treatment of cells with KP-10 in the absence of FBS did not increase IP formation in the
MCF10A. These results reveal that a functionally active KISS1R receptor is present in
parental MCF10A cells, and that both endogenously and exogenously expressed KISS1R
signal in a similar fashion.

KP-10 stimulates EGFR transactivation in non-malignant mammary epithelial cells
and stable transfectants. We have previously shown that KP-10 stimulates migration
and invasion of the ER-negative breast cancer cells MDA-MB-231 and Hs578T via
transactivation of EGFR (Zajac et al., 2011). Therefore, I assessed whether the ERnegative MCF10A cells also undergo KP-10-stimulated EGFR transactivation. Following
stimulation with 100nM KP-10, there was a significant increase in EGFR
phosphorylation levels, compared to non-stimulated MCF10A cells (Figure 2.9). EGF
(positive control) caused a significant phosphorylation of EGFR in these cells. Moreover,
similar observations were made in MCF10A pFLAG-A1 (Figure 2.10A), MCF10A
FLAG-KISS1R (Figure 2.10B) and MCF10A FLAG-KISS1R mixed cells (Figure
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2.10C), whereby KP-10 stimulated EGFR transactivation. Furthermore, AG1478, an
inhibitor of EGFR, blocked KP-10-stimulated EGFR transactivation (Figure 2.10C). KP10 stimulated EGFR transactivation was also blocked upon treatment of cells with
AG1478 in the ER-negative SKBR3 cells (Figure 2.10D). These data suggest that KP
signaling transactivates EGFR in the ER-negative mammary epithelial cells and the ERnegative breast cancer cells.

KP-10 stimulates EGFR transactivation in malignant MCF10Ca1h cells. In a 2001
study, Santner and colleagues reported on the derivation of fully malignant MCF10CA1
lines generated upon Ras-transforming the MCF10A cells that complete the spectrum of
progression from MCF10A to malignant breast cancer cells (Santner et al., 2001). This
well established MCF10 model provides a convenient tool for the investigation of
molecular changes during progression of human breast neoplasia on a common genetic
background (Santner et al., 2001). Since, MCF10A cells undergo KP-10-stimulated
EGFR transactivation (Figure 2.9), I next sought to determine if the MCF10Ca1h cell do
the same. KP-10 stimulated EGFR transactivation in MCF10Ca1h cells which was
subsequently shown to be blocked with the EGFR inhibitor, AG1478 (Figure 2.11).
These data reveal that KP signaling via KISS1R transactivates EGFR not only in
MCF10A cells, but also in Ras-transformed MCF10Ca1h cells. These data indicate that
breast epithelial cells appear to undergo KP-10-stimulated EGFR transactivation
irrespective of their aggressiveness.
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P-234 inhibits KP-10-stimulated EGFR transactivation. To further assess the role of
KISS1R in mediating KP-10-stimulated EGFR transactivation, the KISS1R antagonist
was used to determine the effects on KP-10-stimulated EGFR transactivation.
Pretreatment of MDA-MB-231 breast cancer cells and MCF10A FLAG-KISS1TR cells
with 1µM P-234 inhibited KP-10-stimulated EGFR transactivation. These data suggest
that KP signaling via KISS1R transactivates EGFR in the ER-negative MDA-MB-231
breast cancer (Figure 2.12A) and MCF10A FLAG-KISS1R cells (Figure 2.12B).
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Figure 2.8. KP-10 induces IP production in MCF10A and stable transfectants. IP
formation in MCF10A (A), MCF10A pFLAG-A1 (B), MCF10A FLAG-KISS1R (C) and
MCF10A FLAG-KISS1R mixed cells (D) in the presence or absence of KP-10 (n=5).
Cells were incubated overnight with 1 μCi/mL [3H]myo-inositol in DMEM to radiolabel
inositol lipids. Cells were incubated in either the absence or the presence of 100nM KP10 for one hour at 37°C. Total [3H]inositol incorporated into the cells was determined by
counting the radioactivity present in 50μL of the cell lysate. Total IP was purified from
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the cell extracts by anion exchange chromatography using AG® 1-X8 (analytical grade,
200-400 mesh, formate form) resin (Bio-Rad). [3H]IP formation was determined by LS
6500 Scintillation Counter (Beckman). One-way ANOVA followed by Dunnett’s
multiple comparison test: *, P<0.05. Bars represent % IP Formation ± SEM.
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Figure 2.9. KP-10 stimulates EGFR transactivation in non-malignant mammary
epithelial cells. MCF10A cells were serum-starved for 24 hours, and then left
unstimulated (NS), treated with 10ng/mL EGF (positive control) or 100 nM KP-10 for
the indicated time points and then solubilized in lysis buffer. KP-10 treatment results in
increase of EGFR phosphorylation (n=4). One-way ANOVA followed by Dunnett’s
multiple comparison test: *, P<0.05.
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Figure 2.10. KP-10 stimulates EGFR transactivation in ER-negative cells. (A)
MCF10A pFLAG-A1, (B) MCF10A FLAG-KISS1R, (C) MCF10A FLAG-KISS1R
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mixed and (D) SKBR3 cells were serum-starved for 24 hours, then either left in serumfree medium or pretreated with 500nM AG1478 for one hour, and then left un-stimulated
(NS), treated with 10ng/mL EGF (positive control) or 100 nM KP-10 for the indicated
time points and then solubilized in lysis buffer. KP-10 increases EGFR phosphorylation
(n=3). One-way ANOVA followed by Dunnett’s multiple comparison test: *, P<0.05.
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Figure 2.11. KP-10 stimulates EGFR transactivation in malignant MCF10Ca1h
cells. Cells were serum-starved for 24 hours, then either left in serum-free medium or
pretreated with 500nM AG1478 for one hour, and then left un-stimulated (NS), treated
with 10ng/mL EGF (positive control) or 100 nM KP-10 for the indicated time points and
then solubilized in lysis buffer. KP-10 increases EGFR phosphorylation (n=3). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P<0.05.
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Figure 2.12. P-234 inhibits KP-10-stimulated EGFR transactivation. (A) MDA-MB231 or (B) MCF10A FLAG-KISS1R cells were serum-starved for 24 hours or pretreated
with 1µM P-234, and then either left untreated (NS), treated with 10ng/mL EGF (positive
control) or 100 nM KP-10 for the indicated time points and then solubilized in lysis
buffer. P-234 inhibits KP-10-stimulated EGFR phosphorylation (n=3). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P<0.05.
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KP-10 does not stimulate invasiveness and EGFR transactivation of ER-positive
breast cancer cells. Thus far, my data indicated that KP-10 stimulates invasiveness and
EGFR transactivation in the ER-negative breast epithelia. Next, I sought to determine if
KP-10 induces invasion, motility and EGFR transactivation in the ER-positive, MCF7
and T47D breast cancer cells. KP-10 did not stimulate MCF7 cell invasion in 3D cultures
(Figure 2.13A) or cell migration, using Transwell chambers (Figure 2.13B). To
visualize the effect of KP-10 on cell motility, scratch assays were performed and
although EGF significantly stimulated MCF7 cell motility, KP-10 (10nM or 100nM) did
not enhance scratch closure, when compared to cells in the presence of 10% FBS (Figure
2.13C). Additionally, KP-10 did not transactivate EGFR in MCF7 cells, while
stimulation of cells with EGF (positive control) resulted in EGFR phosphorylation
(Figure 2.13D). We have previously reported that KP-10 does not stimulate migration of
T47D cells (Zajac et al., 2011). Furthermore, KP-10 did not stimulate T47D cells to
invade in 3D cultures (Figure 2.14A) or migrate using scratch assays (Figure 2.14B).
Additionally, T47D cells did not undergo KP-10-stimulated EGFR transactivation
(Figure 2.14C). Thus, these data suggest that the ER status of the cells critically
regulates whether KISS1R signaling stimulates invasiveness and EGFR transactivation,
suggesting that KP-10 may influence metastatic potential of the breast cancer cells that
are deficient of ERα.

ERα expression in the ER-negative MDA-MB-231 attenuates KP-10-induced
migration, invasion and EGFR transactivation. To further ascertain the correlation
between ERα expression and KISS1R signaling, ERα was stably expressed in the ER-
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negative MDA-MB-231 cells (Figure 2.15A). I found that stable expression of ERα
blocked both KP-10-induced migration and invasion (Figure 2.15B), and KP-10stimulated EGFR transactivation (Figure 2.15C), compared to cells expressing the vector
control. Thus, these data suggest that KP-10-stimulated EGFR transactivation depends on
the ER status of breast epithelia.
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Figure 2.13. KP-10 does not stimulate invasion, migration or EGFR transactivation
in the ER-positive MCF7 breast cancer cells. (A) Treatment of MCF7 cells with either
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10 or 100nM KP-10 does not result in invasive stellate structure formation (n=3). (B)
KP-10 does not stimulate migration of MCF7 cells. Results are presented as a ratio of
cells that migrated relative to cells seeded in serum-free medium and migrating towards
10% (v/v) fetal bovine serum-supplemented medium, as was measured by Transwell
chamber assay (n=6). On average 200-300 cell migrated towards 10% FBS per field.
One-way ANOVA followed by Dunnett’s multiple comparison test: *, P<0.05. (C) KP10 does not stimulate the motility of MCF7 cells using a scratch assay (n=3). Two-way
ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for 10ng/mL EGF and 10%
serum when compared to untreated cells; b, P<0.05 for 10ng/mL EGF and 10% serum
when compared to 10% serum. Scale bar, 100 µm. (D) MCF7 cells were serum-starved
for 24 hours, and then left untreated (NS), treated with 10ng/mL EGF (positive control)
or 100 nM KP-10 for the indicated time points and then solubilized in lysis buffer. KP-10
treatment does not lead to EGFR phosphorylation (n=3).
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Figure 2.14. KP-10 does not stimulate invasive stellate structure formation, motility
or EGFR transactivation in the ER-positive T47D breast cancer cells. (A) Treatment
of T47D cells with either 10 or 100nM KP-10 does not result in a stellate structure
formation (n=3). (B) KP-10 does not affect the motility of T47D cells in a scratch assay
(n=3). Scale bar, 100 µm. (C) Cells were serum-starved for 24 hours, and then left
untreated (NS), treated with 10ng/mL EGF (positive control) or 100 nM KP-10 for the
indicated time points and then solubilized in lysis buffer. KP-10 treatment does not lead
to EGFR phosphorylation (n=3).
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Figure 2.15. ERα expression in ER-negative MDA-MB-231 cells abrogates KP-10enhanced migration and EGFR transactivation. (A) A representative Western blot
showing stable expression of ERα in MDA-MB-231 cells. (B) KP-10 (10nM and 100nM)
significantly stimulates cell migration and invasion in MDA-MB-231 pcDNA3.1 (vector
control) cells. ERα expression in MDA-MB-231 cells blocks KP-10-enhanced migration
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and invasion observed in MDA-MB-231 pcDNA3.1 (vector control) cells. Results are
presented as a ratio of cells that migrated relative to cells seeded in serum-free medium
and migrating towards 10% (v/v) fetal bovine serum-supplemented medium, as was
measured by Transwell chamber assay (n=3). On average 400-500 cell migrated towards
10% FBS per field in both MDA-MB-231 pcDNA3.1 and MDA-MB-231 ERα cells.
One-way ANOVA followed by Dunnett’s multiple comparison test: *, P<0.05. Bars
represent % migration ± SEM. (C) KP-10-mediated EGFR transactivation in MDA-MB231 pcDNA3.1, is ablated in MDA-MB-231 ERα cells. Cells were serum-starved for 24
hours, and then left untreated (NS), treated with 10ng/mL EGF (positive control) or 100
nM KP-10 for the indicated time points. (n=3). One-way ANOVA followed by Dunnett’s
multiple comparison test: *, P <0.05. Bars represent % migration ± SEM.
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Exogenous expression of KISS1R induces a partial EMT-like phenotype. Two of the
most important pathways in human breast cancer involve estradiol (E2)/ERα and Ecadherin/Snail/Slug signaling, the latter leading to EMT (Micalizzi et al., 2010). The Ecadherin-Snail-Slug cascade is an important pathway implicated in tumor progression,
invasion and metastasis in human breast cancer (Hajra et al., 2002; Catalano et al., 2004).
The Snail transcription family consisting of members, Snai1 (Snail) and Snai2 (Slug), is
thought to repress E-cadherin expression, leading to EMT (Hajra et al., 2002). EMT is
characterized by a loss of epithelial morphology and acquisition of a more migratory,
spindle-shaped phenotype (Micalizzi et al., 2010). The non-malignant MCF10A cells
have been used as models to study EMT and cell transformation as reported in several
studies (Hugo et al., 2007; Micalizzi et al., 2010).
Since the results thus far have shown that stable expression of KISS1R in the nonmalignant MCF10A and moderately invasive breast cancer cells induces an invasive
phenotype, even in the absence of KP-10 stimulation (Figure 2.3B, Figure 2.4B), I
sought to determine if MCF10A FLAG-KISS1R and SKBR3 FLAG-KISS1R cells have
undergone EMT. MCF10A FLAG-KISS1R and SKBR3-KISS1R cells exhibited a
mesenchymal phenotype, compared to their respective vector controls (Figure 2.16A). I
found that the epithelial marker, E-cadherin was strikingly absent from cell-cell junctions
in MCF10A FLAG-KISS1R cells, compared to MCF10A pFLAG-A1 (vector controls)
cells, where E-cadherin was localized to the cell surface (Figure 2.16B). MCF10A
FLAG-KISS1R cells also exhibited stress fibre formation (Figure 2.16B). Furthermore,
Western blot analysis of EMT markers in MCF10A FLAG-KISS1R cells revealed that
there was an increase in expression of the mesenchymal markers Snail/Slug and N-
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cadherin compared to vector controls (Figure 2.16C). However, we did not observe a
change in E-cadherin expression levels by Western blot analysis in MCF10A FLAGKISS1R cells compared to vector control cells (Figure 2.16C). Western blot analysis of
SKBR3 FLAG-KISS1R cells revealed an increase in mesenchymal markers vimentin and
N-cadhein (Figure 2.16D). Thus, these data suggest that stable expression of KISS1R in
the ER-negative MCF10A and SKBR3 cells induces a partial EMT-like phenotype.
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Figure 2.16. KISS1R expression induces a partial EMT-like phenotype in mammary
epithelial cells. (A) Representative DIC images of MCF10A pFLAG-A1 and FLAGKISS1R, and SKBR3 pFLAG-A1 and FLAG-KISS1R cells. Scale bar, 100 µm. (B)
KISS1R expression in MCF10A cells results in intracellular translocation of E-cadherin,
and stress fiber formation compared to vector controls (n=5). E-cadherin immunostaining
detected using an anti-mouse E-cadherin antibody, followed by Alexa Fluor 488
secondary antibody. F-actin staining using Phalloidin conjugated to Alexa Fluor 555
(red); nuclei stained using Hoechst (blue). (C) Representative Western blots showing
expression levels of E-cadherin and Snail/Slug in MCF10A FLAG-KISS1R cells in
comparison to MCF10A pFLAG-A1 (vector control) cells. Expression levels are
normalized to β-Actin, loading control (n=3). (D) Representative Western blots showing
expression levels of N-cadherin and Vimentin in SKBR3 FLAG-KISS1R cells in
comparison to SKBR3 pFLAG-A1 (vector control) cells. Expression levels are
normalized to β-Actin, loading control (n=3).
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IQGAP1 associates with KISS1R and regulates KP-10-induced breast cancer cell
invasion. IQGAP1 binds to a diverse array of signaling and structural proteins to regulate
various processes including cell polarization, cell invasion, cytoskeleton structure, cellcell adhesion and cell motility (Briggs and Sacks, 2003; Brown and Sacks, 2006). A
study has shown that IQGAP1 protein expression is higher in human invasive ductal
carcinoma relative to normal breast tissue (Briggs and Sacks, 2003; Brown and Sacks,
2006). Since I found that IQGAP1 co-localizes with KISS1R at the leading edge of
motile cells, I next sought to determine whether or not IQGAP1 binds KISS1R and plays
a role in transducing its signals to the cytoskeleton, to thereby stimulate breast cancer cell
invasion. I found that endogenous IQGAP1 associates with FLAG-KISS1R stably
expressed in MDA-MB-231 under basal conditions, and KP-10 treatment did not change
the amount of interaction between these two proteins (Figure 2.17).
I then sought to determine a role for IQGAP1 in KP-10-induced breast cancer
invasiveness. IQGAP1 expression was stably depleted in MDA-MB-231 cells, which
express the highest level of this protein amongst the cell lines tested (Jadeski et al., 2008)
with two different siRNA constructs (Mataraza et al., 2003) (Figure 2.18A). I found that
depletion of IQGAP1 in MDA-MB-231 cells significantly blocked KP-10-induced
migration and invasion (Figure 2.18B). These results implicate IQGAP1 as a novel
regulator of KISS1R-mediated breast cancer cell migration and invasion.
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Figure 2.17. KISS1R associates with IQGAP1 in breast cancer cells. FLAG-KISS1R
interacts with IQGAP1 both in presence and absence of KP-10 in MDA-MB-231 cells
(n=3).
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Figure 2.18. Depletion of IQGAP1 blocks KP-10-induced MDA-MB-231 breast
cancer cell migration and invasion. (A) Western blot analysis of IQGAP1 expression in
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MDA-MB-231 cells stably expressing IQGAP1 siRNA constructs (n=5). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P <0.05. (B) MDA-MB231 scrambled, MDA-MB-231 siIQGAP1 #1 and siIQGAP1 #2 cells were subjected to
Transwell chamber migration and invasion studies. Results are presented as a ratio of
cells that migrated or invaded relative to cells seeded in serum-free medium and
migrating or invading towards 10% (v/v) fetal bovine serum-supplemented medium, as
was measured by Transwell chamber assay (n=3). On average 500-600 MDA-MB-231
scrambled cells migrated towards 10% FBS; 300-400 MDA-MB-231 siIQGAP1 #1 and
siIQGAP1 #2 cells migrated towards 10% FBS. On average 300-400 MDA-MB-231
scrambled cells invaded towards 10% FBS; 100-200 MDA-MB-231 siIQGAP1 #1 and
siIQGAP1 #2 cells invaded toward 10% FBS. One-way ANOVA followed by Dunnett’s
multiple comparison test: *, P<0.05. Bars represent % migration or invasion ±SEM.
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CHAPTER 3: DISCUSSION
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3.1. Discussion
Although studies indicate that KISS1R signaling may correlate positively with
breast tumor progression and metastatic potential (Ulasov et al., 2002; Marot et al., 2007;
Cho et al., 2011), the effect of KISS1R signaling on non-malignant breast epithelia is
currently unknown. KISS1R has been shown to be expressed in normal breast tissue
(Ohtaki et al., 2001) and it has been postulated that KISS1R may to be involved in
development of mammary tissue, although how this occurs is presently unknown.
Additionally, the underlying mechanism by which KISS1R stimulates cell migration and
invasion, processes required for metastasis is largely unknown. Contrary to the initial
hypothesis KP-10 signaling via KISSIR will not stimulate invasion and motility of nonmalignant mammary epithelial MCF10A cells, here I demonstrate for the first time that
KP-10/KISS1R signaling is pro-migratory and pro-invasive in MCF10A cells and breast
cancer cells that are ER-negative. I found that KP-10 transactivates EGFR only in the
ER-negative non-malignant and malignant breast cell lines, but fails to stimulate
migration, invasion or EGFR transactivation in the ER-positive breast cancer cell lines.
Hence, the ER status of breast epithelia critically regulates the ability of KISS1R to
induce an invasive phenotype. Furthermore, KISS1R was found to be localized to the cell
front of motile cells migrating into a wound, where it co-localized with the leading edge
marker, IQGAP1. Furthermore, I identified IQGAP1 as a novel binding partner for
KISS1R in MDA-MB-231 breast cancer cells and showed that KISS1R stimulates breast
cancer cell migration and invasion in an IQGAP1-dependent manner. Progress made in
the understanding of the signaling of the KP-10/KISS1R in this study is summarized in
Table 3.1.
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Table 3.1. Progress made in the understanding of the KP-10/KISS1R signaling in
this study.

MAJOR FINDINGS
ZAJAC ET AL. 2011

CVETKOVIĆ ET AL. 2012
(current findings)

 KP-10 promotes migration and
invasion of the ERα-negative
MDA-MB-231 and Hs578T
breast cancer cells via EGFR
transactivation, concominant
with MMP-9 secretion and
activitity, and have implicated
β-arrestin 2.

Findings from the ERα-negative cells:
 KP-10 increases invasiveness of the
ERα-negative MCF10A cells and
stimulates EGFR transactivation.
 KISS1R is localized to the leading
edge of migratory cells, and colocalizes with IQGAP1.
 Stable expression of KISS1R in
MCF10A and SKBR3 cells
stimulates a partial epithelial-tomesenchymal transition-like
phenotype (EMT).
Finding fromt the ERα-positive breast
cancer cells:
 KP-10 does not affect invasiveness or
EGFR transactivation in the T47D
and MCF7 breast cancer cells.
 Stable expression of ERα in MDAMB-231 cells abolishes KP-10stimulated migration, invasion and
EGFR transactivation.
Mechanism by which KISS1R induces
invasiveness:
 Depletion of IQGAP1 in MDA-MB231 cells blocks KP-10-stimulated
migration and invasion.
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Over the last decade, significant progress has been made in understanding the
complexity of GPCR-RTK signaling. Once seen as isolated receptors connecting
extracellular signals to the activation of G proteins, GPCRs are now regarded as complex
receptors capable of initiating a vast array of signaling pathways, including G proteindependent and -independent signaling, involvement with scaffolding molecules, and
interacting both directly and indirectly with other receptor families. RTKs such as the
EGFR are overexpressed in numerous cancers including breast cancer where signaling
through this receptor contributes to cell survival, proliferation, and invasion (Thomas et
al., 2006; Rodland et al., 2008). Inhibition of EGFR alone using receptor tyrosine kinase
inhibitors, although highly promising clinically, has resulted in limited anti-metastatic
effects due to acquired resistance to these agents (Engelman and Janne, 2008). In
addition to RTKs, GPCRs regulate the responsiveness of cancer cells to external stimuli
(Thomas et al., 2006). GPCRs have been shown to transactivate EGFR via the
serine/threonine kinase PKC (Slack, 2000), the non-RTKs of the Src family (Luttrell and
Lefkowitz, 2002), increased intracellular calcium levels (Zwick et al., 1997) and via βarrestins (Zajac et al., 2011). It is well established that transactivation of EGFR results in
increased proliferation and invasion, two hallmarks of the metastatic process (Thomas et
al., 2006). Our previous work has shown that KP-10, the most potent KP, stimulates
breast cancer cell invasion via transactivation of EGFR, concomitant with MMP-9
secretion and activity, and have implicated β-arrestin 2 in this process (Zajac et al.,
2011). Furthermore, we discovered that KISS1R directly complexes with EGFR, and that
stimulation of breast cancer cells with either KP-10 or EGF regulates the endocytosis of
KISS1R and EGFR (Zajac et al., 2011). Because KISS1R appears to signal via EGFR-
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dependent mechanisms to result in increased invasiveness of breast cancer cells, targeting
both receptors simultaneously could potentially result in increased efficacy compared
with inhibiting either receptor alone.
We have previously shown that KISS1R induces EGFR transactivation in the ERnegative invasive breast cancer cells, namely MDA-MB-231, Hs578T (Zajac et al.,
2011). Here, I show that KISS1R activation by KP-10 also transactivates EGFR in ERnegative moderatvely invasive SKBR3 breast cancer cells and ER-negative nonmalignant mammary epithelial MCF10A cells. MCF10A cells are spontaneously
immortalized mammary epithelial cells, which harbor a basal-like phenotype and are
capable of undergoing EMT spontaneously when plated under sparse conditions (Sarrio
et al., 2008). Therefore, all of the studies with MCF10A cells and the derived stable lines
were performed with cells of high density, to eliminate the influence of confluency on
EMT. Interestingly, we observed that stable exogenous expression of KISS1R in
MCF10A or SKBR3 cells induced a partial EMT-like phenotype in the FLAG-KISS1R
expressing cells, in comparison to vector controls. Additionally, exogenous KISS1R
expression stimulated these cells to acquire an invasive phenotype both in the presence as
well as absence of the ligand. This maybe due to the constitutive activity exhibited by
KISS1R as was previously reported (Pampillo et al., 2009). At the present time we
cannot confirm the existence of constitutive activity because an inverse agonist is not yet
available to test this. But given the observations that have been made and the fact that
constitutive activity has been described for more than 60 wild-type GPCRs (Smit et al.,
2007), it should not be surprising to find that KISS1R does indeed display constitutive
activity. Further support of constitutive KISS1R activity comes from in vivo studies
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performed on the Kiss1−/− and Kiss1r−/− animals (Lapatto et al., 2007). In this study, the
authors document a phenotypic variability observed among Kiss1 knockout female mice
and suggest that one likely explanation for it can be as a result of modest constitutive
KISS1R activity. Moreover, Pampillo and others reported that maximum basal activity of
KISS1R is approximately 5% of the maximum KP-10-induced IP formation in HEK 293
cells transiently expressing KISS1R (Pampillo et al., 2009). Previous studies have shown
that KISS1 and KISS1R mRNA is elevated in breast tumor tissue compared to normal
mammary tissue, and these high levels correlate with the shortest relapse-free survival
(Martin et al., 2005). Hence, it is possible that under pathological conditions such as
breast cancer, upregulation of KP and/or KISS1R may stimulate the mammary epithelial
cells to undergo EMT-like events, acquiring mesenchymal-like phenotypes, ultimately
resulting in enhanced migration and invasion implicated in promoting metastasis (Hugo
et al., 2007).
Spontaneously immortalized non-malignant mammary epithelial MCF10A cell line
arose in culture from MCF10 cells which were originally derived from a thirty-six year
old Caucasian female patient with fibrocystic disease (Soule et al., 1990). MCF10 cells
are diploid, while the MCF10A line has a stable, near-diploid karyotype (Soule et al.,
1990; Yoon et al., 2002) with modest genetic modifications typical of culture-adapted
breast epithelial cells (Yaswen and Stampfer, 2002) including loss of the p16 locus
(Debnath et al., 2003). The cells express normal p53 (Merlo et al., 1995; Debnath et al.,
2003), they do not form colonies in anchorage-independent growth assay, and they do not
form tumors in immunocompromised mice (Heppner and Wolman, 1999). MCF10A cells
grown in 3D reconstituted basement membrane culture (rBM) develop important features
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of normal breast tissue via a well described progression of proliferation, cell cycle arrest,
apical-basolateral polarization, and finally, apoptosis to create a luminal space (Debnath
et al., 2002; Debnath et al., 2003; Underwood et al., 2006). Furthermore, the appearance
of cell nuclei of MCF10A cells forming acini in 3D cultures more closely resemble those
of mammary epithelial cells in tissue than those cultured in monolayer (Lelievre et al.,
1998). Cancer arises from a complex interaction of factors including both genetic
changes as well as changes in the microenvironment (Ingber, 2002; Bissell and Labarge,
2005). The development of 3D culture systems which more closely recapitulate the tissue
microenvironment have allowed for a more detailed investigation of the dynamic and
reciprocal crosstalk between the ECM and nuclear gene expression that may play a
critical role in breast tumorigenesis (Weaver et al., 1995; Lelievre et al., 1998; Weaver
et al., 2002; Underwood et al., 2006).
In order to visualize whether or not KP-10 stimulates motility of non-malignant
mammary epithelial MCF10A cells in real-time, we performed scratch assays as
described (Zajac et al., 2011). We observed that 10nM KP-10 (dissolved in 5% FBS)
significantly enhanced the distance travelled by the MCF10A cells over time, when
compared to cells seeded only in 5% FBS. Similar observations were made for the
MCF10A pFLAG-A1 vector control and MCF10A FLAG-KISS1R cells, and
furthermore we did not observe any significant difference in scratch closure efficiencies
between these cell lines. Previously, we’ve shown that KP-10 (dissolved in 10% FBS)
also enhances motility of MDA-MB-231 cells, when compared to cells seeded only in
10% FBS (Zajac et al., 2011). Previously, studies from our laboratory have shown that
KP-10 does not act as a chemoattractant (Zajac et al., 2011). When MCF10A, MCF10A
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pFLAG-A1 or MCF10A FLAG-KISS1R cells were treated with 10nM KP-10 in the
presence of 10% FBS, I did not observe a difference in cell motility, when compared to
cells seeded in 10% FBS alone. Significant difference in cell motility only occurred in
the presence of 5% FBS. The failure to observe a significant difference between the
aforementioned treatment groups with higher concentrations of FBS could be due to
greater levels of EGF found with the higher FBS. We’ve previously shown that KP-10enhanced motility of MDA-MB-231 cells can be blocked with EGFR inhibitor, AG1478
(Zajac et al., 2011), suggesting the EGFR signaling is responsible for KP-10-enhanced
motility. We propose that greater amount of EGF present in 10% FBS versus 5% FBS
may result in saturation of the EGFR response, and therefore addition of KP-10 does not
result in any further increase in motility. Furthermore, treating cells with only KP-10
(dissolved in media lacking FBS, i.e. serum-free media) did not induce motility of MDAMB-231 cells (Zajac et al., 2011) or MCF10A, MCF10A pFLAG-A1, MCF10A FLAGKISS1R (data not shown), suggesting that FBS is required to stimulate these cells to
migrate.
Accumulating evidence strongly supports a role for scaffolding protein IQGAP1 in
tumorigenesis (Johnson et al., 2009; White et al., 2011). IQGAP1 binds to a diverse array
of signaling and structural proteins to participate in multiple cellular functions including
cell polarization, cell motility, cell invasion, cytoskeletal architecture, and E-cadherinmediated cell-cell adhesion (Briggs and Sacks, 2003). IQGAP1 is localized to sites of
cell-cell adhesion and regulates adherens junction stability (Briggs and Sacks, 2003).
IQGAP1 has been shown to promote tumorigenesis of breast cancer cells (Mataraza et
al., 2003; Jadeski et al., 2008) and is considered to be an oncogene (Johnson et al., 2009;
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White et al., 2011). Depletion of IQGAP1 by siRNA resulted in smaller and less invasive
tumors in vivo (Brown and Sacks, 2006). White and colleagues have shown that IQGAP1
is overexpressed in trastuzumab-resistant human breast epithelial cells and that specific
knockdown of IQGAP1 both enhances the inhibitory effects of trastuzumab in vitro and
abrogates trastuzumab resistance (White et al., 2011). Thus, these findings imply that
IQGAP1 is a potential target for the development of additional therapeutic strategies for
patients with HER2-positive breast cancers.
Here, I have shown that KISS1R is localized to the leading edge of cell membranes
where it co-localizes with IQGAP1 in lamellipodia in motile MCF10A and MCF10A
FLAG-KISS1R cells. This suggests that KISS1R may play a dynamic role in cell
migration and indeed, treatment of cells with the KISS1R antagonist, P-234 inhibits
MDA-MB-231 cell motility, thus, demonstrating the necessity of KISS1R signaling in
this process. P-234 has been shown to inhibit the firing of GnRH neurons in the brain of
the mouse and to reduce pulsatile GnRH secretion in female pubertal monkeys (Roseweir
et al., 2009). Additionally, P-234 inhibited the KP-10-induced release of LH in rats and
mice and blocked the postcastration rise in LH in sheep, rats, and mice (Roseweir et al.,
2009). Therefore, the development of KISS1R antagonists such as P-234 provides a
valuable tool for investigating the physiological and pathophysiological roles of
KP/KISS1R signaling and could offer a unique therapeutic agent for treating cancers and
reproductive disorders.
As previously mentioned, stable expression of KISS1R in non-malignant MCF10A
cells causes abnormal localization of E-cadherin, whereby E-cadherin was no longer
decorating the cell membrane, but rather appeared to be translocated to the intracellular
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compartment of the MCF10A FLAG-KISS1R cells. This finding is supported by Li and
colleagues who have shown that the translocation of IQGAP1 from the cytoplasm to the
cell membrane, inhibits E-cadherin-mediated cell-cell adhesion (Li et al., 1999), and
correlates with E-cadherin dysfunction and tumor dedifferentiation in gastric carcinoma
(Takemoto et al., 2001). These data suggest that IQGAP1 promotes EMT, at least in part,
by reducting E-cadherin-mediated cell-cell adhesion.
MDA-MB-231 cells were previously reported to express the highest amount of
IQGAP1 of the breast cancer cells tested (Jadeski et al., 2008). I found that endogenous
IQGAP1 associates with KISS1R in MDA-MB-231 cells. Furthemore, depletion of
IQGAP1 levels in MDA-MB-231 cells inhibited KP-10-induced cell migration and
invasion, indicating that IQGAP1 plays a key role in KP-10-stimulated migration and
invasion of MDA-MB-231 breast cancer cells. We have previously shown that KISS1R
signals via β-arrestin 2 to regulate breast cancer cell invasion, and have shown that
depletion of β-arrestin 2 blocks invasion, MMP-9 secretion and EGFR transactivation in
MDA-MB-231 breast cancer cells (Zajac et al., 2011). Both IQGAP1 and β-arrestin 2
have been reported to facilitate the scaffolding of the MAPK signaling components
(Brown and Sacks, 2006) suggesting that the association of β-arrestin 2 and IQGAP1
may bring together individual signaling complexes within the same area of the cell to
allow for the spatial regulation of multiple processes including cell migration. Future
studies will investigate the mechanism by which KISS1R signaling via IQGAP1
regulates breast cancer migration, invasion and metastasis and to further characterize the
interactions between KISS1R and IQGAP1.
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KPs have since been identified as major regulators of the hypothalamic-pituitarygonadal axis, via tight modulation of GnRH secretion (Huijbregts and de Roux, 2010).
Regulation of GnRH secretion by estrogen is crucial to normal fertility. Several
mechanisms have been proposed to explain both negative and positive feedback effect of
estrogen on the gonadotropic axis. One of them involves modulation of GnRH secretion
by estrogen, that was found to diminish KISS1 expression in the arcuate nucleus of
gonadectomized mice, suggesting a role for KISS1 downregulation in the negative
feedback effect of E2 (Huijbregts and de Roux, 2010). Studies of knockin mice
expressing an ERα variant that was unable to bind DNA showed that regulation of
hypothalamic KISS1 expression was directly involved in the negative feedback of
estrogen on the gonadotropic axis via a nonclassical pathway (Huijbregts and de Roux,
2010).
ERα-mediated pathways play a crucial role in breast carcinogenesis, and thus, ERα
level is used as a prognostic marker of breast tumors (Clarke et al., 2004). For that
reason, I wanted to determine whether the presence of ERα in breast cancer cells affects
their response to KP-10. Here, for the first time I show that KP-10 does not increase
migration, invasion and motility of the ER-positive T47D and MCF7 breast cancer cells.
Furthermore, these cells do not undergo KP-10-stimulated EGFR transactivaton. These
observations are supported by a previous study that has shown that tamoxifen treatment
of ERα positive MCF7 and T47D cells increased KISS1 and KISS1R levels (Marot et al.,
2007). My findings further support their claim, since the clinical relevance of this
negative regulation of KISS1 and KISS1R by estrogen maybe crucial for the
understanding of breast cancer progression. I found that stable ERα expression in the ER-
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negative MDA-MB-231 blocked KP-10-induced migration, invasion and EGFR
transactivation, providing further support for the negative regulation of KP-10/KISS1R
signaling by ERα. My studies extend onto the findings of Margot and colleagues (2007)
who have observed a significant decrease in KISS1 mRNA levels in ERα-negative MDAMB-231 cells expressing recombinant ERα.
Here, I propose a model for ERα-mediated modulation of KP/KISS1R signaling
(Figure 3.1). In normal healthy mammary epithelia, estrogen signaling through ER is
responsible for maintaining normal breast epithelial growth and function, and thus
preserving homeostatic balance, by keeping KP/KISS1R signaling in check through
transcriptional regulation of KISS1 (Huijbregts and de Roux, 2010). However, in certain
cancers, where ER expression is lost or silenced via DNA methylation as is the case of
ER-negative cancers, the brake keeping KP/KISS1R signaling in check is removed, and
this disinhibition results in increased transcription of KISS1, and consequently increases
signaling through KISS1R ultimately allowing for the non-malignant mammary epithelial
cells to acquire a more migratory and invasive phenotype. To summarize, this study
reveals for the first time that the ER status of mammary cells may dictate whether
KISS1R signaling stimulates invasiveness, thus identifying a novel target for metastasis.
Therefore, a better understanding of the mechanisms that regulate KISS1R signaling,
particularly those that regulate activity immediately after receptor activation is required
to evaluate its potential as a therapeutic target in cancer.
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Figure 3.1. Proposed model for ERα-dependent KP-10/KISS1R signaling. In normal
healthy mammary epithelia, estrogen signaling through ERα is responsible for
maintaining normal breast epithelial growth and function, and thus preserving
homeostatic balance, by keeping KP/KISS1R signaling in check through transcriptional
regulation of KISS. However, in breast cancer, where ERα expression is lost or silenced
as is the case of ERα-negative cancers, the brake keeping KP/KISS1R signaling in check
is removed, and this disinhibition results in increased transcription of KISS1 and KISS1R,
and consequently increases signaling through KISS1R ultimately allowing for the nonmalignant mammary epithelial cells to acquire a more migratory and invasive phenotype.
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